

第3日

2月24日(土)

D A Y 3

Saturday, February 24, 2024

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand

SIOG/JSMO Joint Symposium

- SJS** Sustainable Cancer Care for Older Adults
高齢がん診療のケアモデル：持続可能な診療体制とは 280

Joint Symposium

- J57** New Treatment progress for Bone Metastases What's Next role, beside Palliation, Quality of Life Improvement?
骨転移に対する新しい治療の展開 緩和、QOL改善の次のステップは？ 278

Presidential Symposium

- PSY6** Considering the use of Real World Data for clinical development and daily clinical practice
臨床開発や日常診療のための Real World Data 活用を考える 271
- PSY7** Should cancer treatment be centralized or equalized?
がん診療は集約化か均てん化か 272
- PSY8** New drug loss in new drug development
新規薬剤開発における新しいドラッグロス 274

Symposium

- SY23** Perioperative systemic treatment in early-stage non-small cell lung cancer
非小細胞肺癌に対する周術期治療 274
- SY24** Perioperative chemotherapy for gastric cancer: Role of ICI ? 275
- SY25** Novel Therapy Development and Strategies in HR-Positive Breast Cancer - Looking 5 Years into the Future
HR 陽性乳癌での新規治療開発と戦略 -5 年先の未来を見据えて - 277
- SY26** Current and future of liquid biopsy
リキッドバイオプシーの現在と将来 277
- SY27** Pathology in collaboration with AI
AI と歩む病理学 281
- SY28** Current Status and Issues of Career Support for Pediatric and AYA Cancer Patients and Survivors
小児・AYA 世代がん患者の新規就労支援の現状と課題 302
- SY29** Dermatologic adverse events and appearance care – Global trends and issues –
皮膚障害とアピアランスケア～世界の潮流と課題～ 303
- SY30** Advances in Systemic Therapy in Biliary Tract Cancer
胆道癌における薬物療法の進歩 310

Committee Program

CP6 Women's Oncologists Union Workshop	280
CP7 がん教育は何を目指すのか? ～専門医よ、学校へ行こう!～	305
CP8 Go far, go together! ～ Multidisciplinary care and Careers for Tomorrow: Proposals from JSMO 2024 ～ 遠くへ行きたければみんなで行け! ～明日のチーム医療とキャリアを考える: JSMO2024 からの提案～	311

Meet the Experts

ME14 Immunotherapy for gastroesophageal cancer: A 2024 update	313
ME15 Antibody-drug conjugate and Novel therapy in Lung Cancer	313
ME16 Tumor agnostic HER2-targeted drug development	314
ME17 Systemic therapy for Biliary tract cancer	314

Room 1 (1号館 2F センチュリーホール)

8:20-9:50 Presidential Symposium 6 / 会長企画シンポジウム 6

PSY6 Considering the use of Real World Data for clinical development and daily clinical practice
臨床開発や日常診療のための Real World Data 活用を考える



Chairs : Takehito Shukuya (Juntendo University)
Kenichi Nakamura (National Cancer Center Hospital)
司会 : 宿谷 威仁 (順天堂大学)
中村 健一 (国立がん研究センター中央病院)

PSY6-1 Current Status and Challenges of Real-World Data Utilization - From Standpoint of Academia

Daichi Fujimoto (Internal Medicine III, Wakayama Medical University)

リアルワールドデータ活用の現状と課題～アカデミアの立場から～
藤本 大智 (和歌山県立医科大学附属病院 第三内科学講座)

PSY6-2 Evolution of Real World Evidence (RWE) in Oncology

Lynn McRoy (Pfizer Inc)

PSY6-3 Toward application for approval of drugs using RWD "Government efforts and future challenges"

Daisuke Sato (Ministry of Health, Labour and Welfare, Pharmaceutical Evaluation Division, Pharmaceutical Safety Bureau)

RWDを活用した医薬品の承認申請に向けて ～行政側の取組みと今後の課題～
佐藤 大介 (厚生労働省 医薬局医薬品審査管理課)

PSY6-4 Current status and challenges of RWD utilization from the perspective of a biostatistician

Kouji Yamamoto (Department of Biostatistics, Yokohama City University)

生物統計家から見たRWD活用の現状と課題
山本 絃司 (横浜市立大学 医学部 臨床統計学)

9:50-11:50 Presidential Session 4

PS4 Gastrointestinal Cancer, Hepatobiliary/ Pancreatic Cancer
消化器、肝胆膵



Chairs : Tetsuji Takayama (Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences)
Zev A. Wainberg (UCLA School of Medicine)
Discussants: Li-Tzong Chen (Department of Internal Medicine, Kaohsiung Medical University)
Tae Won Kim (Asan Medical Center)
Sun Young Rha (Yonsei Cancer Center, Yonsei University Health System)
司会 : 高山 哲治 (徳島大学大学院 医歯薬学研究所消化器内科学分野)
Zev A. Wainberg (UCLA School of Medicine)
ディスカッサント: Li-Tzong Chen (Department of Internal Medicine, Kaohsiung Medical University)
Tae Won Kim (Asan Medical Center)
Sun Young Rha (Yonsei Cancer Center, Yonsei University Health System)

PS4-1 GnP vs. mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: Additional data from the GENERATE (JCOG1611) trial

Masato Ozaka (Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
尾阪 将人 (がん研有明病院 肝胆膵内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

PS4-2 Chemotherapeutic Sensitivity of Colorectal Cancer (CRC) With Low RNA WT Homologous Recombination (HRec) Gene Expression

Yoshiaki Nakamura (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan)
中村 能章 (国立がん研究センター東病院 消化管内科)

PS4-3 Zolbetuximab + mFOLFOX6 in 1L advanced gastric/gastroesophageal junction cancer: Japanese subgroup analysis in SPOTLIGHT

Kensei Yamaguchi (Department of Gastroenterological Chemotherapy, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research)
山口 研成 (Department of Gastroenterological Chemotherapy, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research)

13:45-15:15 Presidential Symposium 7 / 会長企画シンポジウム 7

**PSY7 Should cancer treatment be centralized or equalized?
がん診療は集約化か均てん化か**



Chairs : Fumihiko Wakao (Headquarters for Cancer Information Services, National Cancer Center)
Hironobu Minami (Medical Oncology/Hematology, Kobe University School of Medicine)

Discussants : Yuichi Ando (Clinical Oncology and Chemotherapy, Nagoya University Hospital)
Hidetoshi Kawaguchi (Department of Breast Surgery, Matsuyama Red Cross Hospital)
Yoshiyuki Majima (NPO PanCAN Japan)
Chikashi Ishioka (Tohoku University Graduate School of Medicine)

司会 : 若尾 文彦 (国立がん研究センター がん対策情報センター本部)
南 博信 (神戸大学 腫瘍・血液内科学分野)

ディスカッサント : 安藤 雄一 (名古屋大学医学部附属病院 化学療法部)
川口 英俊 (松山赤十字病院 乳腺外科)
眞島 喜幸 (全国がん患者団体連合会 / PanCAN Japan)
石岡 千加史 (東北大学大学院医学系研究科)

PSY7-1 Cancer Treatment Delivery System in Japan

Kengo Haruna (Cancer and Disease Control Division, Public Health Bureau, Ministry of Health, Labour and Welfare)

わが国のがん診療提供体制について

春名 健伍 (厚生労働省 健康・生活衛生局がん・疾病対策課)

PSY7-2 Current status and issues of equalization and centralization of cancer medical care

Fumihiko Wakao (Headquarters for Cancer Information Services National Cancer Center)

がん医療均てん化・集約化の現状と課題

若尾 文彦 (国立がん研究センターがん対策情報センター本部)

HoD3



Chairs : Hiroji Iwata (Aichi Cancer Center)

Seiji Yano (Kanazawa University)

司会 : 岩田 広治 (愛知県がんセンター 乳腺科)

矢野 聖二 (金沢大学医薬保健研究域医学系呼吸器内科学)

HoD3-1 **Breast cancer**

Fumikata Hara (Cancer Institute Hospital of JFCR)

乳腺

原 文堅 (がん研究会有明病院 乳腺内科)

HoD3-2 **Hepatobiliary and Pancreatic Oncology**

Masafumi Ikeda (National Cancer Center Hospital East)

肝胆膵

池田 公史 (国立がん研究センター東病院 肝胆膵内科)

HoD3-3 **Rare Cancer**

Takayasu Kurata (Department of Thoracic Oncology, Kansai Medical University)

希少がん

倉田 宝保 (関西医科大学 呼吸器腫瘍内科学講座)

HoD3-4 **Patient Advocacy**

Kiyotaka Watanabe (Division of Medical Oncology, Department of Medicine, School of Medicine, Teikyo University)

患者支援・サバイバーシップ

渡邊 清高 (帝京大学医学部内科学講座 腫瘍内科)

HoD3-5 **Gastrointestinal Oncology**

Yukiya Narita (Department of Clinical Oncology, Aichi Cancer Center Hospital)

消化器

成田 有季哉 (愛知県がんセンター薬物療法部)

Room 2 (1号館 4F レセプションホール)

8:20-9:50 Symposium 23 / シンポジウム 23

SY23 Perioperative systemic treatment in early-stage non-small cell lung cancer
非小細胞肺癌に対する周術期治療



Chairs : Masahiro Tsuboi (National Cancer Center Hospital East)
Toshiyuki Kozuki (Clinical Research Center, National Hospital Organization Shikoku Cancer Center)

司会 : 坪井 正博 (国立がん研究センター東病院)
上月 稔幸 (国立病院機構 四国がんセンター臨床研究センター)

SY23-1 Perioperative Systemic therapy (Neo-adjuvant therapy)
Jonathan Spicer (Assistant Professor of Surgery, McGill University)

SY23-2 The groundbreaking progress in adjuvant therapy
Keiju Aokage (Division of Thoracic Surgery, National Cancer Center Hospital East)

術後補助療法の革新的な進歩

青景 圭樹 (国立がん研究センター東病院 呼吸器外科)

SY23-3 Perioperative treatment for non-small cell lung cancer with driver gene alterations
Junko Tanizaki (Department of Medical Oncology, Kindai University Faculty of Medicine)

ドライバー遺伝子変異陽性非小細胞肺癌に対する周術期治療

谷崎 潤子 (近畿大学医学部 内科学教室腫瘍内科部門)

SY23-4 Future Perspectives of Perioperative Treatment for Non-Small Cell Lung Cancer
Daichi Fujimoto (Internal Medicine III, Wakayama Medical University)

非小細胞肺癌に対する周術期治療における今後の展望

藤本 大智 (和歌山県立医科大学附属病院 第三内科学講座)

9:50-11:50 Presidential Symposium 8 / 会長企画シンポジウム 8

PSY8 New drug loss in new drug development
新規薬剤開発における新しいドラッグロス



Chairs : Kei Muro (Department of Clinical Oncology, Aichi Cancr Center Hospital)
Toshihiko Doi (National Cancer Center Hospital, Exploratory Oncology Research & Clinical Trial Center)

司会 : 圭 室 (愛知県がんセンター 薬物療法部)
土井 俊彦 (国立がん研究センター先端医療開発センター)

PSY8-KL Anti-cancer drug loss in Japan
Noboru Yamamoto (Department of Experimental Therapeutics, National Cancer Center Hospital)

抗がん剤領域におけるドラッグロス

山本 昇 (国立がん研究センター中央病院 先端医療科)

PSY8-1 Disparities of Cancer Drug Affordability according to Countries, Healthcare Systems, and Financial Resources

Yeon Hee Park (Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)

PSY8-2 CRO Approach
Teruyoshi Okuda (CMIC Holdings CO., Ltd.)

CROのアプローチ

奥田 晃義 (シミックホールディングス株式会社)

PSY8-3 New era of drug loss in innovative drug development and countermeasures that Japan needs to take

Tomoko Hirohashi Nakajima (Immuno-Oncology Development, Astellas Pharma US)

新薬開発における新たなドラッグロスと日本の取るべき対応策

廣橋 (中島) 朋子 (米国アステラス製薬 イムノオoncロジー開発)

PSY8-4 PMDA's Approaches to Tackle the Challenge "Drug Loss"

Yasuhiro Fujiwara (Pharmaceuticals and Medical Devices Agency)

ドラッグ・ロス解消に向けた取り組み

藤原 康弘 (独立行政法人医薬品医療機器総合機構)

13:55-15:15 Symposium 24 / シンポジウム 24

SY24 Perioperative chemotherapy for gastric cancer: Role of ICI ?



Chairs : Daisuke Takahari (Gastroenterological Chemotherapy, Cancer Institute Hospital of JFCR)
Elizabeth Smyth (Oxford Cancer)

Discussants: Izuma Nakayama (Gastroenterological Chemotherapy, Cancer Institute Hospital of the JFCR)
Yukinori Kurokawa (Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine)

Zev Wainberg (UCLA School of Medicine)

Takeshi Kuwata (Department of Clinical Genetics, National Cancer Center Hospital East)

司会 : 高張 大亮 (がん研究会有明病院 消化器化学療法科)

Elizabeth Smyth (Oxford Cancer)

ディスカッサント: 中山 巖馬 (がん研究会有明病院 消化器化学療法科)

黒川 幸典 (大阪大学大学院 消化器外科学)

Zev Wainberg (UCLA School of Medicine)

桑田 健 (国立がん研究センター東病院 遺伝子診療部門)

SY24-KL1 Perioperative chemotherapy for gastric and gastroesophageal junction cancer, European perspective

Elizabeth C. Smyth (Oxford Cancer)

SY24-KL2 Perioperative chemotherapy for gastric cancer: Asian perspective

Kei Muro (Department of Clinical Oncology, Aichi Cancer Center Hospital)

室 圭 (愛知県がんセンター 薬物療法部)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

15:15-16:45 Oral Session 15

O15 Multidisciplinary Team Program
多職種連携プログラム

Chairs : Koji Matsumoto (Division of Medical Oncology, Hyogo Cancer Center)
Hiroshi Nokihara (Department of Respiratory Medicine, Center Hospital of the National Center for Global Health and Medicine)

Discussant : Akiyo Yoshimura (Aichi Cancer Center, Breast oncology)

司会 : 松本 光史 (兵庫県立がんセンター 腫瘍内科)
軒原 浩 (国立国際医療研究センター病院 呼吸器内科)

アシカサト : 吉村 章代 (愛知県がんセンター 乳腺科部)

O15-1 Impact of multidisciplinary intervention on survival time for patients with advanced cancer

Kenichi Takeda (Division of Respiratory Medicine, Matsue city hospital / Cancer center, Matsue city hospital)

多職種による介入が進行期がん患者の生存期間に与える影響

武田 賢一 (松江市立病院 呼吸器内科 / 松江市立病院 がんセンター)

O15-2 Current status of distress screening among cancer patients: A survey of requirements in designated cancer care hospitals

Junna Sakane (Department of Medical Statistics, Research & Development Center, Osaka Medical and Pharmaceutical University / Department of Gastroenterological Surgery, Osaka Medical and Pharmaceutical University)

がん患者に対する苦痛のスクリーニングの現状-がん診療等の指定要件に関する調査より

坂根 純奈 (大阪医科薬科大学医学研究支援センター 医療統計室 / 大阪医科薬科大学 一般消化器外科学)

O15-3 Osteoporosis Treatment in Cancer Patients: Insights and Challenges from Specialized Facilities

Hiroataka Koyanagi (Department of Orthopaedic and Rehabilitation, Saitama Cancer Center)
小柳 広高 (埼玉県立がんセンター 整形外科・リハビリテーション室)

O15-4 Oral hygiene parameters for febrile neutropenia during breast cancer chemotherapy

Shinsuke Sasada (Department of Breast Surgery, Hiroshima University Hospital / Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University)

乳癌化学療法中の発熱性好中球減少症における口腔衛生指標の検討

笹田 伸介 (広島大学病院 乳腺外科 / 広島大学原爆放射線医科学研究所 腫瘍外科)

O15-5 COVID-19 in patients during treatment at the outpatient chemotherapy unit

Shiori Kinoshita (Department of clinical oncology, Nagoya City University / Department of Hematology and Oncology, Nagoya City University)

化学療法室におけるCOVID-19

木下 史緒理 (名古屋市立大学病院 臨床腫瘍部 / 名古屋市立大学病院 血液・腫瘍内科)

Room 3 (1号館 4F 会議室 141+142)

8:20-9:50 Symposium 25 / シンポジウム 25

SY25 Novel Therapy Development and Strategies in HR-Positive Breast Cancer - Looking 5 Years into the Future
HR 陽性乳癌での新規治療開発と戦略 -5 年先の未来を見据えて-Chairs : Toru Mukohara (Department of Medical Oncology, National Cancer Center Hospital East)
Erica Hamilton (Sarah Cannon Research Institute)司会 : 向原 徹 (国立がん研究センター東病院 腫瘍内科)
Erica Hamilton (Sarah Cannon Research Institute)**SY25-1** Future of Novel Hormone Therapy (Oral SERD, 3rd generation SERM, SERCA, PROTAC)
Matthew P. Goetz (Mayo Clinic)**SY25-2** Future of novel molecular targeted drugs (e.g., PI3K, AKT, FGFR, CDK2)
Nicholas Turner (The University of Manchester)**SY25-3** Novel Molecular Biomarkers and Their Applications in Estrogen Receptor-Positive Breast Cancer
Otto Metzger (Dana-Farber Cancer Institute, Harvard Medical School)**SY25-4** Antibody Drug conjugates: A revolution in chemotherapy delivery for breast cancer
Hope S. Rugo (Professor of Medicine and Winterhof Professor of Breast Oncology, University of California San Francisco Comprehensive Cancer Center)

10:05-11:35 Symposium 26 / シンポジウム 26

SY26 Current and future of liquid biopsy
リキッドバイオプシーの現在と将来Chairs : Toru Mukohara (Department of Medical Oncology, National Cancer Center Hospital East)
Maki Tanioka (Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)司会 : 向原 徹 (国立がん研究センター東病院 腫瘍内科)
谷岡 真樹 (岡山大学医歯薬学総合研究科)**SY26-1** Perspective of Minimal Residual Disease (MRD) in Lung Cancer
Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital)
肺癌における Minimal Residual Disease (MRD) の展望
堀之内 秀仁 (国立がん研究センター中央病院 呼吸器内科)**SY26-2** Development of ctDNA for MRD detection in breast cancer
Yukinori Ozaki (Department of Breast Medical Oncology, Department of Advanced Medical Development at The Cancer Institute Hospital of Japanese Foundation for Cancer Research)
乳癌の MRD 検出を目的とした ctDNA の開発
尾崎 由記範 (がん研究会有明病院 乳腺内科, 先端医療開発科)**SY26-3** Circulating tumor DNA-guided therapeutic strategy in patients with resectable and metastatic colorectal cancer
Yoshiaki Nakamura (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)
切除可能および切除不能進行再発大腸がんにおける血液循環腫瘍 DNA を活用した治療戦略
中村 能章 (国立がん研究センター東病院 消化管内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

SY26-4 New epigenetic technologies for ctDNA analysis
Tatsuhiko Shibata (Laboratory of Molecular Medicine, The Institute of Medical Science, The University of Tokyo)

ctDNA 解析の新しい技術

柴田 龍弘 (東京大学医科学研究所 ゲノム医科学分野)

13:55-15:35 Joint Symposium 7 (JASTRO/JSMO) / 合同シンポジウム 7 (日本放射線腫瘍学会 / 日本臨床腫瘍学会)

JS7

New Treatment progress for Bone Metastases What's Next role, beside Palliation, Quality of Life Improvement?

骨転移に対する新しい治療の展開 緩和、QOL改善の次のステップは？



Chairs : Takeshi Kodaira (Aichi Cancer Center Hospital Department of Radiation Oncology)
Sadamoto Zenda (National Cancer Center Hospital East)

司会 : 古平 毅 (愛知県がんセンター 放射線治療部)
全田 貞幹 (国立がん研究センター東病院)

JS7-1 Introduction to skeletal metastasis management

Tatsuya Takagi (Department of Palliative Medicine, Orthopedics, Rehabilitation Medicine, Juntendo University)

骨転移診療の概論

高木 辰哉 (順天堂大学 緩和医療研究室・整形外科・リハビリテーション科)

JS7-2 Palliative Radiotherapy for Bone Metastases

Naoki Nakamura (Department of Radiation Oncology, St. Marianna University School of Medicine)

骨転移に対する放射線治療

中村 直樹 (聖マリアンナ医科大学 放射線治療科)

JS7-3 Stereotactic body radiotherapy for spinal metastases

Kei Ito (Department of Radiation Oncology, Tokyo Metropolitan Komagome Hospital)

脊椎SBRT

伊藤 慶 (東京都立駒込病院 放射線科治療部)

JS7-4 Interventional Radiology for Bone Metastasis: How to use it as a Palliative Therapy?

Yasunori Arai (Department of Diagnostic Radiology, National Cancer Center East Hospital)

骨転移に対するIVR~緩和のツールとしてどう使うか~

荒井 保典 (国立がん研究センター東病院 放射線診断科)

JS7-5 Pharmacotherapy for Bone Metastasis Pain

Hiromichi Matsuoka (Department of Psycho-Oncology, National Cancer Center Hospital / Palliative and Supportive Care Development Division, National Cancer Center Hospital)

骨転移痛に対する薬物療法

松岡 弘道 (国立がん研究センター中央病院 精神腫瘍科 / 国立がん研究センター中央病院 支持療法開発室)

MO36 Head and Neck Cancer 1 (head and neck cancer 1, thyroid cancer, salivary gland cancer, systemic therapy)
 頭頸部 1 (頭頸部癌 1、甲状腺癌、唾液腺癌、全身治療)

E

Chairs : Satoshi Hamauchi (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)
 Kazue Ito (Miyagi Cancer Center)

司会 : 濱内 諭 (静岡県立静岡がんセンター 消化器内科)
 伊東 和恵 (宮城県立がんセンター 頭頸部内科)

MO36-1 Future Treatment Strategies for Advanced Thyroid Cancer Based on Genetic Mutation

Ken-ichi Ito (Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine)
 伊藤 研一 (信州大学医学部外科学教室 乳腺内分泌外科学分野)

MO36-2 Early prediction of treatment outcome for lenvatinib using PET/CT in patients with unresectable thyroid carcinoma

Satoshi Takeuchi (Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University)
 竹内 啓 (北海道大学大学院 医学研究院 腫瘍内科学教室)

MO36-3 Retrospective Analysis of Lenvatinib Use for Anaplastic Thyroid Carcinoma Management in Our Facility

Akira Tsunoda (Department of Medical Oncology, Mie University Hospital)
 角田 瑛 (三重大学医学部附属病院 腫瘍内科)

MO36-4 Salivary gland-type cancers: cross organ demographics of a rare cancer

Aika Tanzawa (Department of Medical Oncology, Graduate School of Medicine, Chiba University)
 丹沢 藍加 (千葉大学大学院医学研究院 臨床腫瘍学講座)

MO36-5 LH-RH agonist monotherapy for AR-positive recurrent and/or metastatic salivary gland cancer: A retrospective study

Takuma Kishida (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)
 岸田 拓磨 (国立がん研究センター東病院 頭頸部内科)

MO36-6 Efficacy and safety of lenvatinib in recurrent or metastatic adenoid cystic carcinoma arising from head and neck area

Kazuki Yokoyama (Department of Head and Neck, Esophageal Medical Oncology National Cancer Center Hospital)
 横山 和樹 (国立がん研究センター中央病院 頭頸部・食道内科)

Day 1 (Thu)
 Day 2 (Fri)
 Day 3 (Sat)
 On-demand
 Room 1
 Room 2
 Room 3
 Room 4
 Room 5
 Room 6
 Room 7
 Room 8
 Room 9
 Room 10
 Room 11
 Room 12
 Room 13
 Meet the Experts
 Poster

Room 4 (3号館 3F 国際会議室)

8:20-9:50 SIOG/JSMO Joint Symposium / SIOG/JSMO 合同シンポジウム

SJS Sustainable Cancer Care for Older Adults
高齢がん診療のケアモデル：持続可能な診療体制とは



Chairs : Tomonori Mizutani (Department of Medical Oncology, Kyorin University Faculty of Medicine)
Madoka Yanagawa (Department of Clinical Oncology and Chemotherapy Nagoya University Hospital)
司会 : 水谷 友紀 (杏林大学医学部 腫瘍内科学)
柳川 まどか (名古屋大学医学部附属病院 化学療法部)

SJS-1 Multidisciplinary Approach to Geriatric Oncology
Lung Tat Andrew Chan (Department of Medicine, Queen Elizabeth Hospital, Hong Kong)

SJS-2 Developing Geriatric Oncology Centers of Excellence, Perspectives from a NCI Cancer Center Director
Andrew E Chapman (Sidney Kimmel Cancer Center, Jefferson Health)

SJS-3 Sustainable model of geriatric oncology care in Japan
Hiroshi Yamamoto (Department of Respiratory Medicine, Tokyo Metropolitan Institute for Geriatrics and Gerontology)

日本における持続可能な老年腫瘍ケアモデル
山本 寛 (東京都健康長寿医療センター 呼吸器内科)

10:20-11:50 Committee Program 6 / 委員会企画 6 (Women's Oncology Union Meeting)

CP6 Women's Oncologists Union Workshop



Chairs : Lynn M. Schuchter (Tara Miller Melanoma Center at the Abramson Cancer Center)
Takako Nakajima (Department of Early Clinical Development, Kyoto University Graduate School of Medicine)
Discussants : Yukari Tsubata (Shimane University Hospital)
Elaine Lim (National Cancer Centre Singapore)
Anna D. Wagner (Lausanne University Hospital and University of Lausanne)
司会 : Lynn M. Schuchter (Tara Miller Melanoma Center at the Abramson Cancer Center)
中島 貴子 (京都大学大学院医学研究科 早期医療開発学)
津端 由佳里 (鳥根大学医学部附属病院 呼吸器・化学療法内科)
Elaine Lim (National Cancer Centre Singapore)
Anna D. Wagner (Lausanne University Hospital and University of Lausanne)

CP6-1 Introduction: Introduction of the session and the activities of JSMO Career Empowerment Committee
Takako Nakajima (Department of Early Clinical Development, Kyoto University Graduate School of Medicine)
中島 貴子 (京都大学大学院医学研究科 早期医療開発学)

CP6-2 Activities and networking of women's oncologist in ASCO and US
Lynn M. Schuchter (Department of Medicine, Hematology Oncology Division, University of Pennsylvania)

CP6-3 **Perspectives of Women Oncologists: Roles and Networking in JSMO and Japan**
Yukari Tsubata (Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine)
津端 由佳里 (島根大学医学部附属病院 呼吸器・化学療法内科)

13:55-15:25 Symposium 27 / シンポジウム 27

SY27 Pathology in collaboration with AI
AI と歩む病理学 

Chairs : Satoshi Fujii (Department of Molecular Pathology, Yokohama City University Graduate School of Medicine) Department of Molecular Pathology, Yokohama City University Graduate School of Medicine)

Akihiko Yoshizawa (Department of Diagnostic Pathology, Nara Medical University)

司会 : 藤井 誠志 (横浜市立大学大学院医学研究科・医学部 分子病理学)
吉澤 明彦 (奈良県立医科大学 病理診断学講座)

SY27-1 **Application of AI in pathological diagnosis of gastric biopsy**
Hiroyuki Abe (Department of Pathology, Graduate School of Medicine, The University of Tokyo)

胃生検病理診断におけるAIの活用

阿部 浩幸 (東京大学大学院医学系研究科 人体病理学・病理診断学)

SY27-2 **Prediction of genetic abnormalities from pathological morphology**
Satoshi Fujii (Department of Molecular Pathology, Yokohama City University Graduate School of Medicine)

病理形態像から遺伝子異常の予測

藤井 誠志 (横浜市立大学大学院医学研究科・医学部 分子病理学)

SY27-3 **The future of "telepathology" using digital innovation**
Akihiko Yoshizawa (Department of Diagnostic Pathology, Nara Medical University)

デジタルイノベーションによる遠隔病理診断の将来像

吉澤 明彦 (奈良県立医科大学 病理診断学講座)

SY27-4 **Frontiers in Image Recognition and Multimodal Models**
Tatsuya Harada (The University of Tokyo / RIKEN / NII)

画像認識とマルチモーダルモデルの最前線

原田 達也 (東京大学 / 理化学研究所 / NII)

16:05-16:45 Mini Oral Session 37

MO37 Clinical Trial Facilitation Program 1
臨床試験推進プログラム 1 

Chairs : Satoru Miura (Niigata Cancer Center Hospital)
Tadaaki Nishikawa (National Cancer Center Hospital, Department of Medical Oncology)

司会 : 三浦 理 (新潟県立がんセンター新潟病院)
西川 忠暁 (国立がん研究センター中央病院 腫瘍内科)

MO37-1 **DECENTRALIZED CLINICAL TRIAL IN A PHASE II TRIAL OF TAZEMETOSTAT FOR PATIENTS WITH EPITHELIOID SARCOMA (TAZETTA TRIAL)**

Shosuke Kita (Department of Medical Oncology, National Cancer Center Hospital)

喜多 昭介 (国立がん研究センター中央病院 腫瘍内科)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

MO37-2
Encore **Phase 1 study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, in adults with advanced solid tumors**
Takako Nakajima (Department of Early Clinical Development, Kyoto University Graduate School of Medicine)
中島 貴子 (京都大学大学院医学研究科 早期医療開発学)

MO37-3 **Construction of data for implementation of comprehensive cancer genome profiling using genome-guided system**
Yu Sunakawa (Department of Clinical Oncology, St. Marianna University School of Medicine / Center for Genomic Medicine, St. Marianna University Hospital)
ゲノムガイドシステムを用いた包括的がんゲノムプロファイリングの実装データの構築
砂川 優 (聖マリアンナ医科大学 臨床腫瘍学講座 / 聖マリアンナ医科大学病院
ゲノム医療推進センター)

MO37-4 **The clinical validity of digital PCR to identify KRAS mutations using plasma or cytology specimens in pancreatic cancer**
Kumiko Umemoto (Department of Clinical Oncology, St. Marianna University School of Medicine)
梅本 久美子 (聖マリアンナ医科大学病院 臨床腫瘍学)

Room 5 (4号館 3F 会議室 431+432)

8:20-9:20 Mini Oral Session 38

MO38 Gastrointestinal Cancer 6 (Others)
消化器 6 (その他)**E**Chairs : Yu Sunakawa (Department of Clinical Oncology, St. Marianna University School of Medicine)
Toshihiro Kudo (Osaka International Cancer Institute)司会 : 砂川 優 (聖マリアンナ医科大学 臨床腫瘍学講座)
工藤 敏啓 (大阪国際がんセンター 腫瘍内科)**MO38-1** **The Effects of the COVID-19 Pandemic on Time to Treatment for Stage III Colonic Adenocarcinoma in the United States**

Bryan Iorgulescu (Division of Pathology and Laboratory Medicine, MD Anderson Cancer Center)

MO38-2 **Clinicopathological features of early-onset colorectal cancer**Yutaka Okagawa (Department of Gastroenterology, Tonan Hospital)
岡川 泰 (斗南病院 消化器内科)**MO38-3** **Comprehensive genomic profiling of advanced anal adenocarcinoma****Encore**
Nozomu Ogura (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)
小倉 望 (国立がん研究センター中央病院 肝胆膵内科)**MO38-4** **Changes in chemotherapy for unresectable or metastatic small bowel adenocarcinoma**Shun Fujiwara (Department Clinical Oncology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan)
藤原 俊 (東京医科歯科大学 臨床腫瘍学)**MO38-5** **A retrospective analysis of the efficacy and safety of imatinib in elderly with advanced gastrointestinal stromal tumor**Takahito Awatsu (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)
栗津 崇仁 (国立がん研究センター中央病院 消化管内科)**MO38-6** **The utility of circulating tumor DNA in gastrointestinal stromal tumor -a pooled analysis of SCRUM-Japan trials-**Tadayoshi Hashimoto (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East / Translational Research Support Office, National Cancer Center Hospital East)
橋本 直佳 (国立がん研究センター東病院 消化管内科 / 国立がん研究センター東病院
トランスレーショナルリサーチ支援室)

9:20-10:20 Mini Oral Session 39

MO39 Gastrointestinal Cancer 7 (Colorectal Cancer, Biomarker)
消化器 7 (大腸がん・バイオマーカー)**E**Chairs : Shunsuke Kato (Dept. Clin. Oncol. Juntendo Univ. Graduate School of Medicine)
Shuichi Hironaka (Department of Medical Oncology, Kyorin University Faculty of Medicine)司会 : 加藤 俊介 (順天堂大学大学院医学研究科 臨床腫瘍学)
廣中 秀一 (杏林大学医学部 腫瘍内科学)**MO39-1** **Clinical Utility of Cancer Gene Panel Testing from Real-World Data: Focusing on Discrepancies between CDx and CGP**Yoshinaga Okugawa (Department of Genomic Medicine, Mie University Hospital)
奥川 喜永 (三重大学医学部附属病院 ゲノム医療部)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

- MO39-2 Clinical significance of plasma-based comprehensive genomic profiling in metastatic colorectal cancer by RAS/BRAF status**
 Kazuki Ogawa (Department of Clinical Oncology, St. Marianna University School of Medicine)
 小川 和起 (聖マリアンナ医科大学 臨床腫瘍学)
- MO39-3 Multi-omics unveils pertuzumab and trastuzumab resistance determinants in ERBB2-amplified metastatic colorectal cancer**
 Naoko Iida (Translational Research Support Office, National Cancer Center Hospital East)
 飯田 直子 (国立がん研究センター東病院 医薬品開発推進部門
 トランスレーショナルリサーチ支援室)
- MO39-4 Significance of somatic or germline homologous recombination-related genes mutation for prognosis in colorectal cancers**
 Yoshiyasu Kono (Department of Gastroenterology, Okayama University Hospital)
 河野 吉泰 (岡山大学病院 消化器内科)
- MO39-5 UBR4 is a novel biomarker for anti-EGFR antibodies in colorectal cancer patients by regulating EGFR internalization**
 Akira Fukuya (Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences)
UBR4はEGFRの内在化を制御することで、大腸癌患者における抗EGFR抗体の新規バイオマーカーとなる
 福家 慧 (徳島大学大学院医歯薬研究部 消化器内科学分野)
- MO39-6 Defeating Colorectal Cancer: Lantadene and Peronemin Compounds Targeting AKT1 and ERK1/2 - Docking & ADMET Assessment**
 Rizki Rachmad Saputra (Department of Chemistry, Universitas Palangka Raya)

10:20-11:20 Mini Oral Session 40

MO40 Gastrointestinal Cancer 8 (Colorectal Cancer, Anti-EGFR antibody)
 消化器 8 (大腸がん・抗EGFR抗体薬) E

Chairs : Hironaga Satake (Department of Medical Oncology, Kochi Medical School)
 Hidekazu Shiota (Department of Clinical Oncology, Tohoku University Hospital)

司会 : 佐竹 悠良 (高知大学 医学部 腫瘍内科学講座)
 城田 英和 (東北大学病院 腫瘍内科)

- MO40-1 Predictors for m-FOLFOXIRI plus cetuximab in RAS/BRAF wild-type and left-sided mCRC: the DEEPER trial (JACCRO CC-13)**
 Soichiro Natsume (Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)
 夏目 壮一郎 (独立行政法人東京都立病院機構 東京都立駒込病院 外科)
- MO40-2 High-methylated colorectal cancer shows a gene expression profile associated with resistance to anti-EGFR antibodies**
 Shonosuke Wakayama (Department of Medical Oncology, Tohoku University Hospital /
 Department of Clinical Oncology, Graduate School of Medicine, Tohoku University)
 若山 祥之介 (東北大学病院 腫瘍内科 / 東北大学大学院医学系研究科 臨床腫瘍学分野)
- MO40-3 Impact of acquired RAS, BRAF and PIK3CA mutation at 8 weeks on the efficacy of anti-EGFR monoclonal antibodies in mCRC**
 Toshihiro Kudo (Department of Medical Oncology, Osaka International Cancer Institute)
 工藤 敏啓 (大阪国際がんセンター 腫瘍内科)

MO40-4 Encore	Anti-EGFR therapy for <i>RAS</i> mutant mCRC without <i>RAS</i> mutations in ctDNA after 1st or 2nd-line chemotherapy: JACCRO CC-17	Day 1 (Thu)
	Yukari Ono (Department of Gastrointestinal Surgery, Kanagawa Cancer Center) 小野 由香利 (神奈川県立がんセンター 消化器外科)	Day 2 (Fri)
MO40-5 Encore	Impact of early tumor shrinkage and depth of response in patients with <i>BRAF</i> V600E-mutant metastatic colorectal cancer	Day 3 (Sat)
	Shohei Udagawa (Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research) 宇田川 翔平 (がん研究会有明病院 消化器化学療法科)	On-demand
MO40-6	Clinical outcome of encorafenib, cetuximab and binimetinib in <i>BRAF</i> V600E-mutated metastatic colorectal cancer	Room 1
	Seiya Sato (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East) 佐藤 清哉 (国立がん研究センター東病院 消化管内科)	Room 2
13:55-14:55 Mini Oral Session 41		
MO41	Rare Cancer 4 (Pediatric・Sarcoma 1) 希少がん 4 (小児・サルコーマ 1)	Room 3
Chairs :	Nami Shirakawa (Department of Clinical Research Support Office / Department of Pediatric Oncology National Cancer Center Hospital) Shin Takahashi (Chemotherapy Center, Sendai Kousei Hospital)	Room 4
司会 :	白川 奈美 (国立がん研究センター中央病院 臨床研究支援部門 / 小児腫瘍科) 高橋 信 (仙台厚生病院 化学療法センター)	Room 5
MO41-1	Palliative Single-agent oral Etoposide; Efficacy and impact on quality of life in pediatric malignancies	Room 6
	Hind Shaheen (Pediatric Oncology Department, Elmataria Teaching Hospital Egypt)	Room 7
MO41-2	演題取下	Room 8
MO41-3	Effectiveness and prospects of eribulin therapy for advanced sarcoma	Room 9
	Yoshihiro Okita (Department of Clinical Oncology, Kagawa University Hospital) 進行肉腫に対するエリブリン使用経験 大北 仁裕 (香川大学医学部附属病院 がんセンター)	Room 10
MO41-4	Importance of local control of primary cardiac sarcomas: a report of 5 cases	Room 11
	Nozomi Nishitarumizu (Department of Hematology and Oncology, Nagoya City University) 西垂水 希美 (名古屋市立大学病院 血液・腫瘍内科)	Room 12
MO41-5	Efficacy of Pomalidomide in Patients with Kaposi Sarcoma: A Systematic Review	Room 13
	Syafna A. Maulidia (Faculty of Medicine, Pelita Harapan University, Indonesia)	Meet the Experts
MO41-6	Chemotherapy for metastatic or recurrent soft tissue sarcoma: real world experience in a single institute	Poster
	Osamu Maeda (Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital) 前田 修 (名古屋大学医学部附属病院 化学療法部)	

Day 1 (Thu)
 Day 2 (Fri)
 Day 3 (Sat)
 On-demand
 Room 1
 Room 2
 Room 3
 Room 4
 Room 5
 Room 6
 Room 7
 Room 8
 Room 9
 Room 10
 Room 11
 Room 12
 Room 13
 Meet the Experts
 Poster

14:55-15:55 Mini Oral Session 42

MO42 Gastrointestinal Cancer 9 (Colorectal Cancer, Angogenesis Inhibitor)
 消化器 9 (大腸がん・血管新生阻害薬) **E**

Chairs : Eiji Shinozaki (Division of gastroenterological chemotherapy, Cancer Institute Hospital of JFCR)
 Hirokazu Shoji (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)

司会 : 篠崎 英司 (がん研究会有明病院 消化器化学療法科)
 庄司 広和 (国立がん研究センター中央病院 消化管内科)

MO42-1 FOLFOXIRI-Bev as First-Line Treatment in Patients with Metastatic Colorectal Cancer: A Systematic Review of RCT
 Brigitta Stephanie Luih (Pelita Harapan University)

MO42-2 Phase II study of FOLFIRI plus aflibercept for colorectal cancer refractory to anti-EGFR antibodies: HGCSG1801
 Hiroshi Nakatsumi (Department of Gastroenterology, NHO Hokkaido Medical Center)
 中積 宏之 (国立病院機構北海道医療センター 消化器内科)

MO42-3 A prospective observational study investigating the impact of treatment sequence on overall survival of mCRC
 Toshiki Masuishi (Department of Clinical Oncology, Aichi Cancer Center Hospital)
 舂石 俊樹 (愛知県がんセンター 薬物療法部)

MO42-4 Randomized phase III study of bi-weekly FTD/TPI plus BEV vs. FTD/TPI monotherapy for chemorefractory mCRC: JCOG2014
 Yasunobu Ishizuka (Department of Clinical Oncology, Aichi Cancer Center Hospital / Department of Medical Oncology, Osaka International Cancer Institute)
 石塚 保亘 (愛知県がんセンター 薬物療法部 / 大阪国際がんセンター 腫瘍内科)

MO42-5 A phase 2 study of inpatient dose escalation of bi-weekly FTD/TPI plus BEV for colorectal cancer (E-BITS study)
 Munehiro Wakabayashi (Department of Clinical Oncology, Aichi Cancer Center Hospital)
 若林 宗弘 (愛知県がんセンター 薬物療法部)

MO42-6 Efficacy and Safety of Tipiracil Combined with Bevacizumab in Metastatic Colon Cancer Patients: A Systematic Review
 Hosea Glory (Faculty of Medicine, Pelita Harapan University)

Room 6 (1号館 3F 会議室 131+132)

8:20-9:20 Mini Oral Session 43

MO43 Genitourinary Cancer 2 (Genitourinary Cancer)
泌尿器 2 (泌尿器がん)**E**

Chairs : Noriyoshi Miura (Ehime University Graduate School of Medicine)
Akiyuki Yamamoto (Department of Urology, Toyohashi Municipal Hospital)

司会 : 三浦 徳宣 (愛媛大学大学院医学系研究科 泌尿器科)
山本 晃之 (豊橋市民病院 泌尿器科)

MO43-1 **Apparent diffusion coefficient histogram in the differentiation of benign and malignant testicular tumors**

Hung Duy Nguyen (Department of Radiology, Hanoi Medical University)

MO43-2 **Adolescence Sexual Behaviors and Urologic Cancer Risks: Meta-analytic Structural Equation Modeling**

Tanan Bejrananda (Faculty of Medicine, Prince of Songkla University)

MO43-3 **Survival outcomes of patients with metastatic germ cell tumors: A verification of treatment trends**

Hiroshi Yaegashi (Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science)

八重樫 洋 (金沢大学大学院医薬保健学総合研究科 泌尿器集学的治療学)

MO43-4 **Impact of new androgen receptor pathway inhibitors (ARPIs) on Sarcopenia in Hormone-Sensitive Prostate Cancer**

Shogo Watanabe (Department of Medical Oncology, Toranomon Hospital)

渡辺 祥伍 (虎の門病院 臨床腫瘍科)

MO43-5 **Prognosis and quality of life in patients undergoing chemotherapy for castration resistant prostate cancer**

Takahito Negishi (Department of Urology, National Hospital Organization Kyushu Cancer Center)

根岸 孝仁 (九州がんセンター 泌尿器・後腹膜腫瘍科)

MO43-6 **UPRISE study: anxiety in patients with urothelial cancer in postoperative period -relation to patient demographics-**

Naoto Morishima (Oncology Medical Affairs, Ono Pharmaceutical, Co., Ltd.)

森島 直士 (小野薬品工業株式会社 オンコロジーメディカルアフェアーズ部)

9:25-10:25 Mini Oral Session 44

MO44 Genitourinary Cancer 3 (Development of Biomarkers of Genitourinary Cancer)
泌尿器 3 (泌尿器がん治療におけるバイオマーカーの開発)**E**

Chairs : Yuji Miura (Toranomon Hospital)

Hiroshi Yaegashi (Department of Urology, Kanazawa University Hospital)

司会 : 三浦 裕司 (虎の門病院 臨床腫瘍科)
八重樫 洋 (金沢大学附属病院 泌尿器科)

MO44-1 **Assessing PSA decline kinetics and Kelim as predictors of survival in docetaxel-treated prostate cancer patients**

Shinro Hata (Department of Urology, Faculty of Medicine Oita University)

羽田 真郎 (大分大学医学部 腎泌尿器外科学講座)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

- MO44-2 Leukemia Inhibitory Factor Signaling Drives Immunosuppression and Neuroendocrine Differentiation in Prostate Cancer**
Yen-Nien Liu (Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University)
- MO44-3 Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide**
Shigekatsu Maekawa (Department of Urology, Iwate Medical University)
COMTタンパクの発現は前立腺癌に対するエンザルタミド療法のバイオマーカーとなりうる
前川 滋克 (岩手医科大学 泌尿器科)
- MO44-4 THE LEVEL OF GENE EXPRESSION OF POLYAMINE METABOLISM PROTEINS IN HUMAN PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA**
Veronika V Bentrad (R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine)
- MO44-5 Circulating microRNA as liquid biopsy biomarker for prediction of oncological outcomes in patients with bladder cancer**
Fumihiko Urabe (Department of Urology, The Jikei University School of Medicine)
占部 文彦 (東京慈恵会医科大学 泌尿器科学講座)
- MO44-6 Preoperative sarcopenia and hypoalbuminemia are poor prognostic factors in nonmetastatic renal cell carcinoma**
Tomoyuki Makino (Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science)
術前のサルコペニアと低アルブミン血症は、非転移性腎細胞癌患者における予後不良因子である
牧野 友幸 (金沢大学大学院医薬保健学総合研究科 泌尿器集学的治療学)
- 13:55-14:55 Mini Oral Session 45

MO45 Multidisciplinary Team Program 3
多職種連携プログラム 3 (チーム医療)

Chairs : Tomoko Taniyama (National Center for Global Health and Medicine, Comprehensive Cancer Center)
Hatoe Sakamoto (Supportive Care Center)

司会 : 谷山 智子 (国立国際医療研究センター病院 がん総合診療センター)
坂本 はと恵 (国立がん研究センター東病院 サポートケアセンター/がん相談支援センター)

- MO45-1 Effectiveness of Short-Duration On-Demand Training in Lung Cancer Patient Care**
Yu Onodera (Asahikawa Medical University Hospital Nursing Department)
短時間の動画コンテンツで構成した肺がん患者のケアに関するオンデマンド型研修の有効性
小野寺 優 (旭川医科大学病院 看護部)
- MO45-2 Current practices in addressing financial toxicity in oncology nursing: a multicenter questionnaire survey**
Sena Yamamoto (Osaka University Graduate School of Medicine, Division of Health Sciences)
がん治療の経済毒性に関する看護実践の現状：多施設共同質問紙調査
山本 瀬奈 (大阪大学大学院医学系研究科 保健学専攻)
- MO45-3 Study on long-term effectiveness and cost of the scalp cooling device in breast cancer patients**
Tomoko Aoki (Department of Nursing, Aichi Cancer Center Hospital)
乳癌患者における頭皮冷却装置の長期的有効性とコストに関する満足度調査
青木 智子 (愛知県がんセンター 看護部)

- MO45-4** **New Initiatives for Urological Cancer Genome Outpatient Services at Our Hospital**
Mizuho Okawa (Department of Urology, Toho University Omori Medical Center)
当施設における泌尿器科がんゲノム外来のとりくみ
大川 瑞穂 (東邦大学医療センター大森病院 泌尿器科)
- MO45-5** **An accomplishment of active interventions by registered dietitians within our outpatients chemotherapy center**
Takashi Shibata (Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Pharmacotherapy)
外来化学療法センター内における管理栄養士による積極的な介入実績
柴田 剛志 (日本赤十字社愛知医療センター名古屋第二病院 薬物療法内科)
- MO45-6** **Collaboration of certified nurses for Esophageal cancer patients receiving chemoradiation**
Naomi Ito (Nursing Department, National Cancer Center Hospital East)
食道がん化学放射線療法を受ける患者に対する認定看護師間の連携
伊藤 直美 (国立がん研究センター東病院 看護部)
-
- 15:30-16:30 Mini Oral Session 46
- MO46** **Hematologic Malignancies 4 (Other (Myeloma etc.))** **E**
血液 4 (その他 (骨髄腫等))
- Chairs : Kazuhito Suzuki (Division of Clinical Oncology/Hematology, the Jikei University School of Medicine)
Shigeki Ito (Hematology and Oncology, Iwate Medical University Hospital)
- 司会 : 鈴木 一史 (東京慈恵会医科大学附属病院 腫瘍・血液内科)
伊藤 薫樹 (岩手医科大学附属病院 血液腫瘍内科)
- MO46-1** **Age and low body mass index were risk factors for thrombotic events in multiple myeloma**
Kazuhito Suzuki (Division of Clinical Oncology and Hematology, the Jikei University School of Medicine)
鈴木 一史 (東京慈恵会医科大学附属病院 腫瘍・血液内科)
- MO46-2** **Identification of prognostic biomarkers corresponding to relapsed/refractory multiple myeloma using a proteomic approach**
Wittawat Chantkran (Department of Pathology, Phramongkutklao College of Medicine, Bangkok, Thailand)
- MO46-3** **Impact of transfusion burden on HRQOL and functioning in patients with myelofibrosis: Post hoc analysis of SIMPLIFY-1/-2**
Encore
Lucia Masarova (The University of Texas MD Anderson Cancer Center, Houston, TX)
- MO46-4** **The Analysis of polycythemia using Yamagata City citizen health checkup data**
Yuichi Kato (Yamagata City Institute of Public Health)
山形市における市民健診データを用いた多血症の実態解析
加藤 裕一 (山形市 健康医療部 (山形市 保健所) 保健所)
- MO46-5** **Efficacy of Quizartinib Acid on Patients with Acute Myeloid Leukemia: A Systematic Review**
Vether Fernhandho (Faculty of Medicine, Pelita Harapan University)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

MO46-6

Comparison of Surgery, Radiotherapy, Chemotherapy, or in Combination in Histiocytic Sarcoma: A Systematic Review

Marchella Tjandra (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)

Room 7 (1号館 3F 会議室 133+134)

8:20-9:20 Mini Oral Session 47

MO47 Rare Cancer 5 (Cancer of Unknown Primary, Other)
希少がん 5 (原発不明がん, その他)**E**Chairs : Hiromichi Ebi (Division of Molecular Therapeutics, Aichi Cancer Center)
Yusuke Onozawa (Shizuoka Cancer Center)司会 : 衣斐 寛倫 (愛知県がんセンター がん標的治療TR分野)
小野澤 祐輔 (静岡県立静岡がんセンター 原発不明科)**MO47-1 The efficacy and safety of nivolumab for cancer of unknown primary**Hiroko Kaiume (National Cancer Center Hospital)
貝梅 絢子 (国立がん研究センター中央病院)**MO47-2 Simvastatin synergizes the anti-tumor effects of temsirolimus in renal cell carcinoma cells by activating LKB1 and AMPK**

Shu-Hui Juan (Department of Physiology, Taipei Medical University)

MO47-3 A Survey of phase I clinical trials for rare cancer patients in our department

Erisa Toda (Department of Advanced Medical Development Center, The Cancer Institute Hospital of JFCR / Department of Medical Oncology, Toranomon Hospital)

当科における希少がん患者の第I相試験実態調査

戸田 恵有沙 (がん研究会有明病院 先端医療開発科 / 虎の門病院 臨床腫瘍科)

MO47-4 Neutrophil-Lymphocyte Ratio Predicts Prognosis in Bone Metastasis: Meta-Analysis of Retrospective Studies

Hans M. Gunawan (Faculty of Medicine, Pelita Harapan University)

MO47-5 Progression Free Survival of Larotrectinib in Patients With NTRK Fusion-positive Tumors: a Systematic Review

Mattheo MA Sumampow (Universitas Pelita Harapan)

MO47-6 Treatment experience of 5 cases of primary mediastinal germ cell tumors at our hospital

Satoshi Nishiyori (Department of Medical Oncology, Kyushu University)

当院での縦隔原発胚細胞腫瘍5例の治療経験

西依 慧 (九州大学病院 腫瘍内科)

9:20-10:20 Mini Oral Session 48

MO48 Rare Cancer 6 (Sarcoma 2)
希少がん 6 (サルコーマ 2)**E**

Chairs : Satoshi Takeuchi (Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University)

Masashi Ando (Aichi Cancer Center Hospital, Department of Clinical Oncology)

司会 : 竹内 啓 (北海道大学 大学院医学研究院 腫瘍内科学教室)
安藤 正志 (愛知県がんセンター 薬物療法部)**MO48-1 C-Reactive Protein as Prognostic Factor in Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis**

Amos I. Chandra (Faculty of Medicine, Pelita Harapan University)

MO48-2 Cardiotoxicity After High Cumulative Dose of Anthracyclines in Adults with Advanced Soft Tissue Sarcomas: a Meta-Analysis

Paula Isabel G. Franco (Cancer Institute, St. Luke's Medical Center, Quezon City)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

MO48-3 Clinical Outcomes of Soft Tissue Sarcoma (STS) in the Philippines: A Single-center Experience

Encore

Omar P Maano (St. Luke's Medical Center)

MO48-4 Survival outcomes of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective KMOG study

Kenji Tsuchihashi (Department of Hematology, Oncology and Cardiovascular Medicine)
土橋 賢司 (九州大学病院 血液・腫瘍・心血管内科)

MO48-5 Third-line chemotherapy for recurrent/refractory rhabdomyosarcoma in adults: a single-center retrospective study

Toru Imai (Department of Medical Oncology, National Cancer Center Hospital)
今井 亨 (国立がん研究センター中央病院 腫瘍内科)

MO48-6 Diagnostic performance of Magnetic Resonance Imaging in discriminating benign and malignant soft tissue tumors

Encore

Tam Thi Nguyen (Hanoi Medical University)

10:20-11:20 Mini Oral Session 49

MO49 Patient Advocacy 2
患者支援 2 (コミュニケーション/その他)

Chairs : Hisakazu Nishimori (Department of Hematology, Hiroshima City Hiroshima Citizens Hospital)
Saiko Kurosawa (Ina Central Hospital, Department of Oncology)

司会 : 西森 久和 (広島市立広島市民病院 血液内科)
黒澤 彩子 (伊那中央病院 腫瘍内科)

MO49-1 Optimal Video Duration for Sustaining Viewership and Engagement in Breast Cancer Treatment Information

Atsushi Fushimi (Department of Breast and Endocrine Surgery, The Jikei University School of Medicine / General Incorporated Association, BC Tube)
伏見 淳 (東京慈恵会医科大学外科学講座 乳腺内分泌外科 / 一般社団法人 BC Tube)

MO49-2 Impact of Patient and Public Involvement (PPI) in development of recommendations for cancer genomic medicine in Japan

Nana Akiyama (Department of Genomic Medicine, University of Tokyo Hospital)

がんゲノム医療推進に向けた提言書作成における患者・市民参画 (PPI: Patient and Public Involvement) の意義

秋山 奈々 (東京大学医学部附属病院 ゲノム診療部)

MO49-3 Survey of differences in patients' and physicians' perceptions of the pain of cancer drug side effects

Taku Kojima (St. Marianna University School of Medicine)

患者と主治医の抗がん剤による副作用のつらさと休薬希望度の差に関する意識調査

小島 拓 (聖マリアンナ医科大学)

MO49-4 Development of team-based care using electronic reporting of PRO-CTCAE in outpatients receiving chemotherapy

Saiko Kurosawa (Department of Oncology, Ina Central Hospital)

薬物療法患者における ePRO を用いた有害事象モニタリング：地域のがん診療連携拠点病院腫瘍内科外来における経験

黒澤 彩子 (伊那中央病院 腫瘍内科)

MO49-5 Appropriate SDM and ACP are required during chemotherapy for advanced stage cancer; concerns seen in the SAE database

Hideki Tsujimura (Chiba Cancer Center, Division of Medical Oncology)

**進行期悪性腫瘍に対するがん薬物療法中には適切なSDMとACPが求められる；
重篤な有害事象データベースから見えた課題**

辻村 秀樹 (千葉県がんセンター 外来化学療法科)

MO49-6 Unscheduled visits Hospital for elderly cancer patients

Kanae Kawamura (National Cancer Center Hospital East Nursing Department)

高齢がん患者における緊急受診の実態調査

川村 香奈恵 (国立がん研究センター東病院 看護部)

13:55-15:05 Mini Oral Session 50

**MO50 Hepatobiliary/ Pancreatic Cancer 4 (Pancreatic Cancer 4 (Gallbladder and Biliary Tract Cancer 2)
肝胆膵 4 (膵臓 4 (胆嚢・胆道 2))**

E

Chairs : Kohei Nakachi (Tochigi Cancer Center)

Yasuyuki Kawamoto (Division of Cancer Center, Hokkaido University Hospital)

司会 : 仲地 耕平 (栃木県立がんセンター)

川本 泰之 (北海道大学病院 消化器内科・腫瘍センター)

MO50-1 A Review of Comprehensive Genomic Profiling of Cholangiocarcinoma in Japan

Emiko Tange (Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)

丹下 絵美子 (東京都立駒込病院 腫瘍内科)

MO50-2 Association between HRD and TTF to platinum-based chemotherapy for biliary tract cancer by using the C-CAT database

Kazunaga Ishigaki (Department of Chemotherapy, Graduate School of Medicine, The University of Tokyo / Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo)

石垣 和祥 (東京大学医学部附属病院 外来化学療法部 / 東京大学医学部附属病院 消化器内科)

MO50-3 TCOG T3221 Study: The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer

Nai-Jung Chiang (Department of Oncology, Taipei Veterans General Hospital, Taiwan / National Institute of Cancer Research, National Health Research Institutes, Taiwan)

MO50-4 Clinical utility of ctDNA-based versus tissue-based genomic profile testing for patients with biliary tract cancer

Shiro Kimbara (Medical Oncology and Hematology, Kobe University Graduate School of Medicine)

金原 史朗 (神戸大学医学部附属病院 腫瘍・血液内科)

MO50-5 Clinical characteristics of MSI-H hepatobiliary and pancreatic cancer: A multicenter observational study

Kenji Ikezawa (Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute)

池澤 賢治 (大阪国際がんセンター 肝胆膵内科)

MO50-6 Characterization of patients with advanced biliary tract cancer by KRAS alteration subtypes

Taro Shibuki (Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan / Department for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Support Office, National Cancer Center Hospital East)

澁木 太郎 (国立がん研究センター東病院 肝胆膵内科 / 国立がん研究センター東病院 医薬品開発推進部門医薬品開発推進部トランスレーショナルリサーチ支援室)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

MO50-7 Evaluation of preoperative chemotherapy and cancer genome therapy for intrahepatic cholangiocarcinoma in our hospital
Takashi Matsumoto (Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University)
松本 嵩史 (熊本大学大学院 消化器外科学)

15:20-16:30 Mini Oral Session 51

MO51 Hepatobiliary/ Pancreatic Cancer 5 (Liver Cancer)
肝胆胰 5 (肝胆胰 (肝臓)) E

Chairs : Satoshi Shimizu (Saitama Cancer Center)
Tatsuya Yamashita (Department of Gastroenterology, Kanazawa University Hospital)
司会 : 清水 怜 (埼玉県立がんセンター 消化器内科)
山下 竜也 (金沢大学附属病院 消化器内科)

MO51-1 Phase Ib trial of durvalumab plus tremelimumab with particle therapy in HCC with macrovascular invasion: DEPARTURE trial
Encore
Keisuke Koroki (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan)
興紹 慧輔 (千葉大学大学院医学研究院 消化器内科学)

MO51-2 Patient and Physician Preferences for Systemic Therapy Combined with TACE for Hepatocellular Carcinoma
Junji Furuse (Department of Gastroenterology, Kanagawa Cancer Center)
古瀬 純司 (神奈川県立がんセンター)

MO51-3 Impact of Oncostatin M expression in tumor microenvironment of hepatocellular carcinoma on pathological features
Yasuyuki Shigematsu (Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)
重松 康之 (がん研究会有明病院 病理部)

MO51-4 Peripheral T cell subpopulations during atezolizumab plus bevacizumab treatment for hepatocellular carcinoma
Yasutoshi Fujii (Department of Clinical Oncology, Hiroshima University Hospital)
藤井 康智 (広島大学病院 がん化学療法科)

MO51-5 Combination treatment of Lenvatinib and TACE for unresectable HCC: Short-term outcomes
Yozo Sato (Department of Diagnostic & Interventional Radiology, Aichi Cancer Center Hospital)
佐藤 洋造 (愛知県がんセンター 放射線診断・IVR部)

MO51-6 Efficacy and Safety of Triple vs Dual Combination Therapy with TACE, TKI, and ICI in Unresectable HCC: A Meta-Analysis
Encore
Omar P Maano (St. Luke's Medical Center)

MO51-7 演題取下

Room 8 (2号館 3F 会議室 234)

13:55-14:55 Mini Oral Session 52

MO52 Gynecologic Cancer 2
婦人科 2**E**

Chairs : Kittipat Charoenkwan (Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University)
Tadaaki Nishikawa (National Cancer Center Hospital, Department of Medical Oncology)

司会 : Kittipat Charoenkwan (Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University)
西川 忠暁 (国立がん研究センター中央病院 腫瘍内科)

MO52-1 **A Systematic Review and Integrated Bioinformatic Analysis of Candidate Genes and Pathways in Cervical Cancer****Encore**

Nazefah Abdul Hamid (Department of Basic Medical Sciences I, Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia)

MO52-2 **YinYang 1 (YY1) and P53 Gene Expression Analysis in Cervical Cancer and Its Relationship with Cancer Staging**

Jacobus Jeno Wibisono (Department of Obstetric and Gynecologic Medicine, Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)

MO52-3 **Cervical Cancer Risk factor classifying using data mining and machine learning approach to early diagnosis and treatment**

Mst. Fatema Akter (Biochemistry and Molecular Biology Department, Gono Bishwabidyalay)

MO52-4 **Efficacy of Pembrolizumab as an Adjuvant Therapy vs Chemotherapy in Patients with Cervical Cancer: A Systematic Review**

Maria Esperanza (Pelita Harapan University)

MO52-5 **NAMPT, a novel uterine leiomyoma therapeutic target, governs extracellular matrix modulation environment**

YiFen Chiang (School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University)

MO52-6 **Results of treatment for FIGO stage I-II vulvar squamous cell carcinoma at Viet Nam National Cancer Hospital**

Anh Quang Nguyen (Vietnam National Cancer Hosoiatal)

15:30-16:30 Mini Oral Session 53

MO53 Translational Research/ Clinical Pharmacology 3 (TR in Breast Cancer)
TR・臨床薬理 3 (橋渡し研究 (バイオマーカー研究、効果予測含))**E**

Chairs : Makiko Ono (Department of Medical Oncology/Advanced Medical Development Center, Cancer Institute Hospital of JFCR)
Yumiko Koi (Department of Breast Oncology, NHO Kyushu Cancer Center)

司会 : 小野 麻紀子 (がん研究会 有明病院 総合腫瘍科/先端医療開発科)
厚井 裕三子 (九州がんセンター 乳腺科)

MO53-1 **Tumour Suppressor microRNAs (200a, 200b, miR205 & miR 145) and Breast Cancer Stem Cells in patients of Breast carcinoma**

Shailendra Dwivedi (Department of Biochemistry, All India Institute of Medical Sciences Gorakhpur-273008, India)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

MO53-2 Harnessing Artificial Intelligence and Big Data for Prognostic Advancements in Hormone Receptor-Positive Breast Cancer
Takashi Takeshita (Department of Breast and Endocrine Surgery, Kumamoto City Hospital)
竹下 卓志 (熊本市立熊本市民病院 乳腺・内分泌外科)

MO53-3 Unlocking the Potential: Antihistamine Use and Breast Cancer Risk in Women with Type 2 Diabetes Mellitus
Szu-Yuan Wu (Asia University, Taiwan / Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan)

MO53-4 Sacituzumab Govitecan-Hziy as Treatment in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of RCTs
Jean Andrina Liem (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)

MO53-5 An HRD scoring system based on long-focal copy number alterations that predicts PARP inhibitor response
Encore
Maria Gurileva (BostonGene, Corp.)

MO53-6 Impact of prior anticancer therapy on tumor mutational burden in patients with metastatic breast cancer
Kaede Baba (Department of Pharmacy, National Cancer Center Hospital East)
馬場 楓 (国立がん研究センター東病院 薬剤部)

Room 9 (2号館 3F 会議室 232+233)

8:20-9:50 Oral Session 16

O16 Hematologic Malignancies

血液

E

Chairs : Won Seog Kim (Sungkyunkwan univ school of medicine, Samsung medical center)
Wee Joo Chng (National University of Singapore)

Discussant : Eisei Kondo (Department of Hematology, Kawasaki Medical School)

司会 : Won Seog Kim (Sungkyunkwan univ school of medicine, Samsung medical center)
Wee Joo Chng (National University of Singapore)

プレゼンター: 近藤 英生 (川崎医科大学 血液内科学)

O16-1 Pirtobrutinib in cBTKi Pre-treated Mantle Cell Lymphoma (MCL):**Encore Updates from the Phase 1/2 BRUIN Study**

Koji Izutsu (Department of Hematology, National Cancer Center Hospital)
伊豆津 宏二 (国立がん研究センター中央病院 血液腫瘍科)

O16-2 Predicting the responder for pralatrexate against PTCL: a post hoc analysis of PDX-JP1 study

Yutaka Shimazu (Kyoto Innovation Center for Next Generation Clinical Trials and iPSC Cell Therapy, Kyoto University Hospital / Department of Early Clinical Development, Graduate School of Medicine, Kyoto University / Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University)

島津 裕 (京都大学医学部附属病院 次世代医療・iPS細胞治療研究センター 早期医療開発科 / 京都大学大学院医学研究科 早期医療開発学 / 京都大学大学院医学研究科 血液・腫瘍内科学)

O16-3 The impact of Geriatric Nutrition Risk Index on prognosis in patients with DLBCL

Shin Lee (Department of Hematology, Matsunami General Hospital)
李 心 (松波総合病院 血液内科)

O16-4 Mitigating the Risk of Cytokine Release Syndrome (CRS) in Cycle 1: Preliminary DLBCL Data From the EPCORE NHL-1 Trial

Julie M Vose (University of Nebraska Medical Center)

O16-5 Epcoritamab in Japanese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: EPCORE NHL-3 Longer-Term Data

Koji Izutsu (Department of Hematology, National Cancer Center Hospital)
伊豆津 宏二 (Department of Hematology, National Cancer Center Hospital)

9:50-10:50 Mini Oral Session 54

M054 Head and Neck Cancer 2 (Head and Neck Cancer 2, Systemic Therapy)

頭頸部癌 2 (頭頸部癌 2、全身治療)

E

Chairs : Tomoko Yamazaki (Department Head and Neck Oncology Division, Saitama Medical University International Medical Center)

Takuma Onoe (Department of Medical Oncology)

司会 : 山崎 知子 (埼玉医科大学国際医療センター 頭頸部腫瘍科)

尾上 琢磨 (兵庫県立がんセンター 腫瘍内科)

M054-1 Predictive and prognostic value of p16 in HNSCC patients treated with MTAs and ICI: subgroup analysis of TRIUMPH study

Hyerim Ha (Department of Internal Medicine, Inha University Hospital, College of Medicine, Inha University)

Meet the Experts

Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

MO54-2 Predictive factor of early failure in squamous cell carcinoma of head and neck patients with pembrolizumab monotherapy
Kenji Nakano (Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
仲野 兼司 (がん研究会有明病院 総合腫瘍科)

MO54-3 The response characteristics of pembrolizumab containing regimens for Recurrent or Metastatic Head and Neck Cancer
Jun Taguchi (Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University)
田口 純 (北海道大学大学院医学研究院 腫瘍内科学教室)

MO54-4 Prognostic significance of haematological biomarkers in patients with head and neck cancer treated with nivolumab
Yoh-ichiro Iwasa (Department of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine)
岩佐 陽一郎 (信州大学医学部 耳鼻咽喉科頭頸部外科)

MO54-5 Efficacy and safety of initiating 400 mg every 6 weeks pembrolizumab dosing in patients with head and neck cancer
Yoshiki Kojitani (Department of Medical Oncology, Osaka International Cancer Institute)
梶谷 嘉起 (大阪国際がんセンター 腫瘍内科)

MO54-6 Treatment of oral cancer and role of a medical oncologist
Yosuke Kito (Department of Medical Oncology, Ishikawa Prefectural Central Hospital)
木藤 陽介 (石川県立中央病院 腫瘍内科)

10:50-11:50 Mini Oral Session 55

MO55 Head and Neck Cancer 3 (Head and Neck Cancer 3, Local Therapy)
頭頸部 3 (頭頸部癌 3、局所治療) E
Chairs : Akihisa Wada (Department of Otorhinolaryngology-Head and Neck Surgery, Nagoya University Graduate School of Medicine)
Yosuke Kito (Department of Medical Oncology, Ishikawa Prefectural Central Hospital)
司会 : 和田 明久 (名古屋大学大学院医学系研究科 頭頸部・感覚器外科学講座 耳鼻咽喉科学)
木藤 陽介 (石川県立中央病院 腫瘍内科)

MO55-1 Comparing the Oncologic Outcomes of Proton Therapy and IMRT for Head and Neck Squamous Cell Carcinoma
Wan Ming Chen (Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan)

MO55-2 Outcomes of postoperative radiotherapy after salvage neck dissection for cervical lymph node recurrence in oral cancer
Takeshi Fujisawa (Department of Radiation Oncology, National Cancer Center Hospital East / Division of Radiation Oncology and Particle Therapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center)
藤澤 建志 (国立がん研究センター東病院 放射線治療科 / 国立がん研究センター先端医療開発センター 粒子線医学開発分野)

MO55-3 Statin Use during Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Cancer
Wan Ming Chen (Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan)

- MO55-4** **Investigating the association between osteopontin and risk of head and neck cancer**
Cheng-Chih Huang (Department of Otolaryngology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Taiwan)
- MO55-5** **TRANSORAL ENDOSCOPIC THYROIDECTOMY BY VETIBULAR APPROACH IN VIET NAM: SURGICAL OUTCOMES AND MID-TERM FOLLOW-UP**
Hien Xuan Nguyen (Departement of Oncology, Hanoi Medical University, Vietnam / Departement of Oncology & Palliative Care, Hanoi Medical University Hospital, Vietnam)
- MO55-6** **REtrospective Study of definitive therapy for head and neck mUcosal Melanoma: the RESUME study**
Encore
Yasushi Shimizu (Department of Medical Oncology, Hokkaido University Hospital)
清水 康 (北海道大学病院 腫瘍内科)
- 13:55-14:55 Mini Oral Session 56
- MO56** **Cross-sectional Program 3 (Translational Research/Medical Education)**
臓器横断プログラム 3 (トランスレーショナルリサーチ / 医療者教育)
- Chairs : Yasuhiro Koh (Center for Biomedical Sciences/Internal Medicine III, Wakayama Medical University)
Rika Sakai (Kanagawa Cancer Center)
- 司会 : 洪 泰浩 (和歌山県立医科大学 バイオメディカルサイエンスセンター / 内科学第三講座)
酒井 リカ (神奈川県立がんセンター)
- MO56-1** **Genetic analysis of tumor cells derived from the stress of immune response for understanding of immunotherapy**
Encore
Tomoyuki Ishiguro (Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University)
がん免疫療法における免疫応答ストレスに由来する腫瘍細胞の遺伝子解析
石黒 智之 (昭和大学病院 腫瘍内科学)
- MO56-2** **Effects of polymorphisms in *NR1I2* and *ABC* transporter on the exposure-response of afatinib in patients with NSCLC**
Hayato Yokota (Department of Pharmacy, Akita University Hospital)
非小細胞肺癌患者におけるアファチニブの効果と血中濃度に及ぼすプレグナンX受容体およびABCトランスポーター遺伝子多型の影響
横田 隼人 (秋田大学医学部附属病院 薬剤部)
- MO56-3** **Survey of Driver Gene Testing in Non-Small Cell Lung Cancer Patients**
Kazuo Hasegawa (NPO Lung Cancer Patients Group One Step / Alliance for Lung Cancer / Japan Lung Cancer Alliance)
非小細胞肺癌患者におけるドライバー遺伝子検査実態調査 全国200病院のDPCデータ予備的解析結果
長谷川 一男 (肺がん患者の会ワンステップ / 一般社団法人アライアンス・フォー・ラング・キャンサー / 日本肺がん患者連絡会)
- MO56-4** **Real-world data on comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer**
Masaki Ishida (Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan / Department of Cancer Genome Medical Center, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan)
がん遺伝子パネル検査によりドライバー遺伝子変異を検出した非小細胞肺癌患者の検討
石田 真樹 (京都府立医科大学附属病院 呼吸器内科 / 京都府立医科大学附属病院 がんゲノム医療センター)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

MO56-5 Cultivating the Vanguard: Five Year Experience of Novel Training Program of Precision Cancer Medicine
Sadakatsu Ikeda (Department of Precision Cancer Medicine, Tokyo Medical and Dental University Hospital)

がんゲノム医療若手医師養成の5年間の先駆的取り組み
池田 貞勝 (東京医科歯科大学病院 がんゲノム診療科)

MO56-6 A survey of patient and provider perspectives of telemedicine in oncology -Responses from health care providers
Hiroya Taniguchi (Department of Clinical Oncology, Aichi Cancer Center Hospital / Telemedicine in medical oncology SIG, Japanese Telemedicine and Telecare Association)

がん患者および医療従事者を対象とした腫瘍内科領域における遠隔医療に関する意識調査 -医療従事者からの回答結果報告-
谷口 浩也 (愛知県がんセンター 薬物療法部 / 日本遠隔医療学会 腫瘍内科遠隔医療分科会)

15:30-16:30 Mini Oral Session 57

MO57 Gastrointestinal Cancer 10 (Esophageal Cancer, Metastatic, CRT)
消化器 10 (食道がん・切除不能, CRT) E

Chairs : Keisho Chin (Department of Outpatient Chemotherapy, Cancer Institute Hospital of JFCR)
Shigenori Kadowaki (Department of Clinical Oncology, Aichi Cancer Center Hospital)
司会 : 陳 勁松 (がん研究会 有明病院 外来化学療法部)
門脇 重憲 (愛知県がんセンター薬物療法部)

MO57-1 A randomized phase III study comparing 2-weekly DCF with CF in patients with metastatic esophageal cancer: JCOG1314
Encore
Shuichi Hironaka (Department of Medical Oncology, Kyorin University Faculty of Medicine)
廣中 秀一 (杏林大学医学部 腫瘍内科学)

MO57-2 Results of a phase 2 trial of E7389-LF+nivolumab (NIVO) in patients (pts) with gastric (GC) or esophageal cancers (EGC)
Akihito Kawazoe (National Cancer Hospital East, Kashiwa, Japan)
川添 彬人 (National Cancer Hospital East, Kashiwa, Japan)

MO57-3 Effect of Immunochemotherapy Time-of-day Infusion, Sequence and Interval on Prognosis of Advanced Esophageal Cancer
Shujie Huang (Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China / Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China)

MO57-4 Immune status of the tumor microenvironment and the effect of post-nivolumab chemotherapy in esophageal cancer
Yusuke Amanuma (Department of Gastroenterology, Chiba Cancer Center)
天沼 裕介 (千葉県がんセンター 消化器内科)

MO57-5 The biomarker analysis of atezolizumab following definitive chemoradiotherapy for unresectable locally advanced ESCC
Hideaki Bando (Department of Gastroenterology and Gastrointestinal Oncology)
坂東 英明 (国立がん研究センター東病院 消化管内科)

MO57-6 **Definitive concurrent chemoradiotherapy in patients of synchronous esophageal and head and neck cancer in Vietnam**

Giap Ngoc Hoang (Department of Medical Oncology No. 3, K Hospital)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13


Meet the Experts

Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Room 10 (2号館 2F 会議室 224)

8:20-9:50 Symposium 28 / シンポジウム 28

SY28 Current Status and Issues of Career Support for Pediatric and AYA Cancer Patients and Survivors
小児・AYA 世代がん患者の新規就労支援の現状と課題 

Chairs : Chikako Shimizu (Department of Breast and Medical Oncology, National Center for Global Health and Medicine)
Hatoe Sakamoto (Supportive Care Center, National Cancer Center Hospital East / Cancer Consultation Support Center)
司会 : 清水 千佳子 (国立国際医療研究センター病院 がん総合診療センター／乳腺・腫瘍内科)
坂本 はと恵 (国立がん研究センター東病院 サポートケアセンター／がん相談支援センター)

SY28-1 Transition issues for childhood cancer survivors
Tomoko Taniyama (Comprehensive Cancer Center, National Center for Global Health and Medicine)

小児がん経験者のトランジションの課題
谷山 智子 (国立国際医療研究センター病院がん総合診療センター サバイバーシップ支援科)

SY28-2 Childhood and adolescent cancer survivors' job-seeking and support needs
Naoko Maeda (Department of Pediatrics, National Hospital Organization Nagoya Medical Center)

小児・A世代がんサバイバーの就職活動と支援ニーズ
前田 尚子 (国立病院機構名古屋医療センター 小児科)

SY28-3 Challenges in Supporting First Time Employment for CCS -from a Nurse's Perspective
Kumiko Hashimoto (St. Luke's International Hospital)

CCS(小児がん経験者) の新規就労支援の課題 ～看護師の立場から～
橋本 久美子 (聖路加国際病院)

SY28-4 Support for returning home and school: From a rehabilitation standpoint
Ryo Tobita (Rehabilitation Units, Shiga University of Medical Science Hospital)

自宅復帰・復学に向けた支援 (リハビリの立場から)
飛田 良 (滋賀医科大学医学部附属病院 リハビリテーション部)

SY28-5 Current situation and issues of support for employment in pediatrics
Aya Suzuki (National Center for Child Health and Development)

小児領域における就労に向けた支援の現状と課題
鈴木 彩 (国立成育医療研究センター)

SY29 Dermatologic adverse events and appearance care - Global trends and issues -
皮膚障害とアピアランスケア～世界の潮流と課題～

- Chairs : Keiko Nozawa (Mejiro University)
Akiyo Yoshimura (Aichi Cancer Center)
- Panelists : Tetsuhiro Yoshinami (Center for Cancer Genomics and Personalized Medicine, Osaka University Hospital)
Yoshio Kiyohara (Shizuoka Cancer Center)
Junya Sato (Shonan University of Medical Science)
Keiko Yamamoto (Hyogo Cancer Center)
Shoko Toma (National Cancer Center Hospital Appearance Support Center)
- 司会 : 野澤 桂子 (目白大学)
吉村 章代 (愛知県がんセンター 乳腺科部)
- パネリスト : 吉波 哲大 (大阪大学医学部附属病院 がんゲノム医療センター)
清原 祥夫 (静岡がんセンター)
佐藤 淳也 (湘南医療大学 薬学部)
山本 佳子 (兵庫県立がんセンター)
藤間 勝子 (国立がん研究センター中央病院アピアランス支援センター)

SY29-KL **Cutaneous Toxicities to Cancer Therapies - Advancing science and care of patients and survivors**

Anisha B. Patel (Department of Dermatology, University of Texas MD Anderson Cancer Center)

13:55-14:55 Mini Oral Session 58

MO58 Lung Cancer/ Thoracic Cancer 6 (Small Cell Lung Cancer • Other Thymic Malignancies)
呼吸器 6 (小細胞癌・その他胸部腫瘍)

- Chairs : Yutaka Fujiwara (Aichi Cancer Center, Thoracic Oncology)
Masayuki Takeda (Department of Cancer Genomics and Medical Oncology, Nara Medical University)
- 司会 : 藤原 豊 (愛知県がんセンター 呼吸器内科/感染制御部)
武田 真幸 (奈良県立医科大学 がんゲノム・腫瘍内科)

MO58-1 **Phase 2 small cell lung cancer (SCLC) cohort of liposomal eribulin given with nivolumab: overall survival (OS) update**Hisato Kawakami (Kindai University Faculty of Medicine, Osaka Sayama, Japan)
川上 尚人 (Kindai University Faculty of Medicine, Osaka Sayama, Japan)**MO58-2** **Safety and efficacy Second-line chemotherapy for patients with small cell lung cancer with interstitial lung disease**Matsuda Suguru (Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan)
松田 賢 (静岡県立静岡がんセンター)**MO58-3** 演題取下**MO58-4** **The impacts of G-CSF on the therapeutic efficacy of chemoimmunotherapy for extensive-stage small cell lung cancer**Yuki Tsukazaki (Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University)
塚崎 佑貴 (徳島大学大学院医歯薬学研究所 呼吸器・膠原病内科学分野)**MO58-5** **Clinical outcomes of advanced thymic neuroendocrine neoplasms treated with palliative chemotherapy**Hitomi Shiozaki (Department of Respiratory Medicine, Juntendo University)
塩崎 瞳 (順天堂大学医学部附属順天堂医院 呼吸器内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

MO58-6 Genetic variants in mitochondria contribute the risk of familial lung cancer
Sheng Hsiung Yang (Chest Division, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan / Ph.D. Program in Translational Medicine, National Taiwan University and Academia Sinica, Taipei, Taiwan)

15:00-16:30 Oral Session 17

O17 Lung Cancer/ Thoracic Cancer 3 

Chairs : Nagio Takigawa (General Internal Medicine 4, Kawasaki Medical School)
Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital)

Discussants: Kiyotaka Yoh (National Cancer Center Hospital East)
Kei Kunimasa (Osaka International Cancer Institute)

司会 : 瀧川 奈義夫 (川崎医科大学 総合内科学4)
堀之内 秀仁 (国立がん研究センター中央病院 呼吸器内科)
アシカサト: 葉 清隆 (国立がん研究センター東病院 呼吸器内科)
國政 啓 (大阪国際がんセンター)

O17-1 CheckMate 77T: neoadjuvant chemo + NIVO followed by surgery and adjuvant NIVO for previously untreated, resectable NSCLC

Encore
Fumihiko Tanaka (Second Department of Surgery, University of Occupational and Environmental Health)
田中 文啓 (産業医科大学 医学部第2外科学)

O17-2 Phase II trial of Dostarlimab+chemotherapy (CT) vs pembrolizumab+CT in metastatic non-squamous NSCLC: Primary results

Encore
Solange Peters (Oncology Department, Centre Hospitalier Universitaire Vaudois)

O17-3 Phase II Study of Nivolumab Plus Ipilimumab with Chemotherapy for NSCLC with Untreated Brain Metastases: LOGiK2004

Kentaro Tanaka (Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)
田中 謙太郎 (九州大学大学院医学研究院 呼吸器内科学)

O17-4 Prospective observational study to identify a predictive blood marker for checkpoint inhibitor pneumonitis (CS-Lung 004)

Kakuhiro Yamaguchi (Hiroshima University Hospital, Departement of Respiratory Medicine)
山口 寛博 (広島大学病院 呼吸器内科)

O17-5 Clinical impact of ¹⁸F-FDG-PET/CT in predicting ICI-induced ILD in patients with lung cancer

Satoshi Watanabe (Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences)
渡部 聡 (新潟大学医歯学総合病院 呼吸器・感染症内科)

Room 11 (2号館 2F 会議室 221)

8:20-9:00 Mini Oral Session 59

MO59 Clinical Trial Facilitation Program 2
臨床試験推進プログラム 2Chairs : Mayu Yunokawa (Cancer Institute Hospital of JFCR)
Hiroshi Miyamoto (Department of Gastroenterology and Oncology, Tokushima University
Graduate School of Biomedical Sciences)司会 : 温泉川 真由 (がん研究会有明病院 総合腫瘍科 兼 婦人科)
宮本 弘志 (徳島大学大学院医歯薬学研究部 消化器内科学)**MO59-1** An investigator-initiated phase II trial of tirabrutinib in patients with relapsed or refractory secondary CNS lymphoma

Wataru Munakata (Department of Hematology, National Cancer Center Hospital)

再発/治療抵抗性二次性中枢神経系リンパ腫に対するチラブルチニブ単剤療法の第II相医師主導
治験 (NCCH2201/CRYSTAL 試験)

棟方 理 (国立がん研究センター中央病院 血液腫瘍科)

MO59-2 Ramucirumab + Erlotinib for advanced NSCLC harboring EGFR L858R mutation:
A multicenter retrospective observational studyMasashi Ishihara (Division of Medical Oncology, Department of Internal Medicine, Teikyo
University School of Medicine)EGFR L858R 陽性進行再発NSCLC に対する Ramucirumab + Erlotinib 併用療法:
Trial in Progress (REAL-SPEED study group)

石原 昌志 (帝京大学医学部内科学講座 腫瘍内科)

MO59-3 BELLWAVE-008: Nembtabrutinib vs Chemotherapy for Treatment-Naive Chronic
Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Encore

Shang-Ju Wu (National Taiwan University Hospital)

MO59-4 進行頸部食道扁平上皮癌患者に対して Docetaxel/Cisplatin/5-FU と強度変調放射線治療
IMRT を同時併用する根治的放射線療法第II相試験

Akinori Watanabe (Department of Gastroenterology, Kitasato University School of Medicine)

渡辺 見識 (北里大学医学部 消化器内科学)

9:45-11:15 Committee Program 7 (Board-certified Oncologists Association Program) / 委員会企画 7 (専門医協会企画)

CP7 がん教育は何を目指すのか? ~専門医よ、学校へ行こう!~Chair : Toshimi Takano (Breast Medical Oncology Department, The Cancer Institute Hospital of JFCR)
座長 : 高野 利実 (がん研有明病院乳腺内科)**CP7-1** がん教育の現状 ~教育現場は何を求めているのか~

Kenichi Ishii (Tokyo Metropolitan Nakano Special Support School)

石井 健一 (東京都立中野特別支援学校 主幹教諭)

CP7-2 がん教育はどうあるべきか ~がん経験者の視点から~

Aya Miyoshi (Non-profit organization Cancer Support Kagoshima)

三好 綾 (特定非営利活動法人がんサポートかごしま)

CP7-3 がん教育はどうあるべきか ~がん専門医の視点から~

Tomoko Taniyama (National Center for Global Health and Medicine)

谷山 智子 (国立国際医療研究センター病院 がん総合診療センター サバイバーシップ支援科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

CP7-4

JSMO 専門医部会がん教育プロジェクトの提案

Toshimi Takano (Breast Medical Oncology Department, The Cancer Institute Hospital of JFCR)
高野 利実 (がん研有明病院乳腺内科)

Room 12 (2号館 2F 会議室 222+223)

8:20-9:20 Mini Oral Session 60

MO60 Translational Research/ Clinical Pharmacology 4 (ccDNA and Phase I)
TR・臨床薬理 4 (TR・臨床薬理 (臨床薬理))

E

Chairs : Yasuhiro Koh (Center for Biomedical Sciences/Internal Medicine III, Wakayama Medical University)

Hideaki Bando (National Cancer Center Hospital East)

司会 : 洪 泰浩 (和歌山県立医科大学 バイオメディカルサイエンスセンター /内科学第三講座)

坂東 英明 (国立がん研究センター東病院)

MO60-1 Platelet RNA Signatures in Lung Cancer: Implications for Liquid Biopsy and Tumor-Platelet Crosstalk

Kazuko Sakai (Department of Genome Biology, Kindai University Faculty of Medicine)

がん患者血小板RNA (pltRNA) の遺伝子プロファイルのリキッドバイオプシーへの応用

坂井 和子 (近畿大学医学部 ゲノム生物学教室)

MO60-2 Detection of copy number alterations in plasma of East Asian cancer patients

Steven Olsen (Department of Medical and Clinical Affairs, Guardant Health AMEA)

MO60-3 Aggregated analysis of integrated whole exome (WES) and whole transcriptome (WTS) sequencing in 1,000 cancer patients

Konstantin Chernyshov (BostonGene, Corp.)

MO60-4 Plasma *ERBB2* gene alteration profiling in East Asian cancer patients

Steven Olsen (Department of Medical and Clinical Affairs, Guardant Health AMEA)

MO60-5 Patient characteristics related to screening failure and dropout in Phase I trials

Haruka Ozaki (Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research / Department of Medical Oncology, Toranomon Hospital)

第I相試験においてスクリーニング不適合、脱落となる患者の背景因子の探索

尾崎 遥 (がん研有明病院 先端医療開発科 / 虎の門病院 臨床腫瘍科)

MO60-6 Single-center study: retrospective study of response rates in Phase I trials

Masahiro Kuno (Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research / Department of Medical Oncology, Toranomon Hospital)

単施設研究: 第I相試験の奏効率に関する後方視的検討

久野 真弘 (がん研有明病院 先端医療開発科 / 虎の門病院 臨床腫瘍科)

10:20-11:20 Mini Oral Session 61

MO61 Hematologic Malignancies 5 (Lymphoma 3)
血液 5 (リンパ腫 3)

E

Chairs : Yutaka Shimazu (Department of Early Clinical Development, Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University Hospital)

Shigeru Kusumoto (Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital)

司会 : 島津 裕 (京都大学医学部附属病院次世代医療・iPS細胞治療研究センター 早期医療開発科)

楠本 茂 (愛知県がんセンター 血液・細胞療法部)

MO61-1 Efficacy of DA-EPOCH-R as First-line Therapy for Diffuse Large B-Cell Lymphoma: A Comprehensive Review and Meta-analysis

Muhammad Alifian R. Putra (Department of Internal Medicine, Universitas Indonesia)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

- MO61-2 Clinical outcome of Tirabrutinib against relapse or refractory primary central nervous system lymphoma**
Shohei Kikuchi (Department of Hematology, Toyama University Hospital)
再発・難治中枢神経原発悪性リンパ腫に対するチラブルチニブの治療成績
菊地 尚平 (富山大学附属病院 血液内科)
-
- MO61-3 A 71-year-old man who experienced 5 reactivations of SARS-COV2 after obinutuzumab maintenance therapy**
Takehiko Morioka (Division of Clinical Oncology, Hiroshima Prefectural Hospital)
森岡 健彦 (県立広島病院 臨床腫瘍科)
-
- MO61-4 Safety and Efficacy of Brentuximab Vedotin in Hodgkin's Lymphoma: Systematic Review**
Chrisya Jasmine (Pelita Harapan University)
-
- MO61-5 Associations between plasma levels of C-reactive protein and venetoclax in patients with acute myeloid leukemia**
Masayuki Kobayashi (Department of Hematology, Tokyo Metropolitan Bokutoh Hospital / Bokutoh Hospital-Meiji Pharmaceutical University Joint Research Center)
小林 真之 (東京都立墨東病院 血液内科 / 墨東病院・明治薬科大学連携研究センター)
-
- MO61-6 Efficacy of Enasidenib on Acute Myeloid Leukemia: A Systematic Review**
Reynard C.E Fu (Faculty of Medicine, Pelita Harapan University)
-
- 13:55-14:55 Mini Oral Session 62
-
- MO62 Breast Cancer 5 (Perioperative Chemotherapy)** E
乳腺 5 (周術期治療)
- Chairs : Nobuhiro Shibata (Cancer Treatment Center, Kansai Medical University Hospital)
Yukinori Ozaki (The Cancer Institute Hospital of JFCR)
- 司会 : 柴田 伸弘 (関西医科大学附属病院がんセンター)
尾崎 由紀範 (がん研有明病院 乳腺内科)
-
- MO62-1 Neoadjuvant Pembrolizumab + Chemo vs Placebo + Chemo Followed by Adjuvant Pembrolizumab vs Placebo for Early-Stage TNBC**
Encore
Masato Takahashi (Department of Breast Surgery, Hokkaido University Hospital)
-
- MO62-2 Efficacy and tolerability of KEYNOTE-522 regimen for Japanese population: A single institute retrospective study**
Yosuke Aoyama (Breast Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
青山 陽亮 (がん研究会有明病院 乳腺センター)
-
- MO62-3 Real-world evidence of FN-related hospitalization for shared decision-making on G-CSF use in patients with breast cancer**
Tetsuhiro Yoshinami (Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University)
吉波 哲大 (大阪大学大学院医学系研究科 乳腺・内分泌外科)
-
- MO62-4 Retrospective study of the awareness rate of cognitive dysfunction during perioperative chemotherapy for breast cancer**
Kaho Utsunomiya (Ehime University Hospital Breast Center)
宇都宮 果歩 (愛媛大学医学部附属病院 乳腺センター)

MO62-5 **NEOADJUVANT CHEMOTHERAPY TREATMENT TRIPLE-NEGATIVE BREAST CANCER WOMEN YOUNGER THAN 45 YEARS OF AGE**
Anh Dinh (Department of Medical Oncology, Cancer Research and Clinical Trials Center, Vietnam National Cancer Hospital)

MO62-6 **POOR RESPONSE TO NEOADJUVANT CHEMOTHERAPY OF METAPLASTIC BREAST CANCER: A SINGLE INSTITUTION ANALYSIS**
Long Thanh Nguyen (Department of Medical Oncology No. 6, Vietnam National Cancer Hospital)

15:00-16:00 Mini Oral Session 63

MO63 Breast Cancer 6 (Biomaker)
乳腺6 (バイオマーカー)

E

Chairs : Tatsuya Toyama (Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences)

Mikiya Ishihara (Department of Medical Oncology, Osaka International Cancer Institute)

司会 : 遠山 竜也 (名古屋市立大学大学院医学研究科 乳腺外科学分野)

石原 幹也 (大阪国際がんセンター 腫瘍内科)

MO63-1 **Proportion of Breast Cancer with TMB-H in C-CAT Database**
Yuko Takano (Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital / Department of Breast and Endocrine Surgery, Nagoya University Hospital)
高野 悠子 (名古屋大学医学部附属病院 化学療法部 / 名古屋大学医学部附属病院 乳腺・内分泌外科)

MO63-2 **Clinical practice of OncotypeDX in our institute: A Comparative Analysis of Cases Before and After Approval**
Tomoka Mamori (Okayama University Hospital, Department of Breast and Endocrinological Surgery)
間森 智加 (岡山大学病院 乳腺・内分泌外科)

MO63-3 **Early detection of breast cancer risk prediction using decision tree model based on machine learning technology**
Mst. Mahmuda Khatun (Biochemistry and Molecular Biology Department, Mawlana Bhashani Science and Technology University)

MO63-4 **Utility of IHC-based markers for predicting pathological complete response in early-stage triple-negative breast cancer**
Chikako Funasaka (Department of Experimental Therapeutics National Cancer Center Hospital East / Department of Medical Oncology, National Cancer Center Hospital East)
船坂 知華子 (国立がん研究センター東病院 先端医療科 / 国立がん研究センター東病院 腫瘍内科)

MO63-5 **Prognostic impact of cancer genomic profile testing for metastatic breast cancer in clinical practice**
Ippei Fukada (Genomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research / Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research)
深田 一平 (がん研究会有明病院 ゲノム診療部 / がん研究会有明病院 乳腺内科)

MO63-6 **Utility of comprehensive genomic profiling for malignant breast tumors - a single institutional experience**
Yuri Ozaki (Department of Breast and Endocrine Surgery, Nagoya University)
尾崎 友理 (名古屋大学医学部附属病院 乳腺・内分泌外科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Room 13 (2号館 1F 展示室 211)

8:20-9:50 Symposium 30 / シンポジウム 30

SY30 Advances in Systemic Therapy in Biliary Tract Cancer
胆道癌における薬物療法の進歩



Chairs : Makoto Ueno (Kanagawa Cancer Center)
Nobumasa Mizuno (Department of Gastroenterology, Aichi Cancer Center Hospital)
司会 : 上野 誠 (神奈川県立がんセンター 消化器内科)
水野 伸匡 (愛知県がんセンター 消化器内科部)

SY30-1 Current status and future development of biliary tract cancer in Korea
Do-Youn Oh (Medical Oncology, Seoul National University Hospital)

SY30-2 The Progress of Firstline Chemotherapy in Biliary Tract Cancer in Japan
Tatsuya Ioka (Oncology Center, Yamaguchi University Hospital / Department of Gastroenterological, Breast and Endocrine Surgery, Graduate School of Medicine, Yamaguchi University)

日本における胆道癌薬物治療の進歩 (一次化学療法)

井岡 達也 (山口大学医学部附属病院腫瘍センター / 山口大学大学院医学研究科 消化器・腫瘍外科学)

SY30-3 Current status and future development of second-line or later systemic treatment for advanced biliary tract cancer
Chigusa Morizane (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)

胆道癌の二次治療以後の薬物療法の現状と今後の開発

森實 千種 (国立がん研究センター中央病院 肝胆膵内科)

SY30-4 Clinical significance of gut microbiota in biliary tract cancer
Shun Tezuka (Department of Gastroenterology, Kanagawa Cancer Center)

胆道癌における腸内細菌の臨床的意義について

手塚 瞬 (神奈川県立がんセンター 消化器内科肝胆膵)

SY30-5 Current Status and Future Prospects for Perioperative Treatment of Biliary Tract Cancer
Kohei Nakachi (Tochigi Cancer Center, Department of Medical Oncology)
仲地 耕平 (栃木県立がんセンター 腫瘍内科)

9:50-11:20 Oral Session 18

O18 Breast Cancer
乳腺



Chairs : Sung-Bae Kim (Asan Medical Center, University of Ulsan College of Medicine)
Shigehira Saji (Department of Medical Oncology, Fukushima Medical University)
Discussants: Sung-Bae Kim (Asan Medical Center, University of Ulsan College of Medicine)
Yen-Shen Lu (Department of Oncology, National Taiwan University Hospital)
司会 : Sung-Bae Kim (Asan Medical Center, University of Ulsan College of Medicine)
佐治 重衡 (福島県立医科大学 腫瘍内科学講座)
プレゼンター: Sung-Bae Kim (Asan Medical Center, University of Ulsan College of Medicine)
Yen-Shen Lu (Department of Oncology, National Taiwan University Hospital)

O18-1 Prognostic Impact of Adjuvant Endocrine Therapy by Age for ER-positive and HER2-negative T1a/bN0M0 Breast Cancer

Encore Kaori Terata (Department of Breast and Endocrine Surgery, Akita University Hospital)
寺田 かおり (秋田大学医学部附属病院 乳腺・内分泌外科)

018-2 Second interim Analysis of REIWA study (JBCRG-C07), Observational study of gene panel testing in metastatic breast cancer

Hiroshi Tada (Department of Surgery, Division of Breast and Endocrine Surgery, Tohoku University Hospital)

多田 寛 (東北大学病院総合外科 乳腺・内分泌グループ)

018-3 A phase III study comparing T-DM1 with HPD in older patients with HER2-positive metastatic breast cancer (JCOG1607)

Encore

Akihiko Shimomura (Department of Breast and Medical Oncology, National Center for Global Health and Medicine)

下村 昭彦 (国立国際医療研究センター病院 乳腺・腫瘍内科)

018-4 Post-T-DXd treatment in patients with HER2-positive metastatic breast cancer: A multicenter cohort study (EN-SEMBLE)

Kazuki Nozawa (Department of Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan)

能澤 一樹 (愛知県がんセンター 乳腺科部)

018-5 Sacituzumab govitecan in Japanese patients with metastatic triple negative breast cancer: Phase 2 results of ASCENT J02

Yoichi Naito (Experimental Therapeutics, National Cancer Hospital East)

内藤 陽一 (国立がん研究センター東病院 先端医療科)

13:55-15:25 Committee Program 8 / 委員会企画 8 (会員委員会・キャリアエンパワメント委員会合同企画)

CP8

Go far, go together! ~ Multidisciplinary care and Careers for Tomorrow: Proposals from JSMO 2024 ~
遠くへ行きたいければみんなで行け! ~明日のチーム医療とキャリアを考える: JSMO2024からの提案~



Chairs : Yuka Kobayashi (Nagaoka Chuo General Hospital)

Teruhisa Azuma (Nara Prefecture General Medical Center)

司会 : 小林 由夏 (長岡中央総合病院 腫瘍内科)

東 光久 (奈良県総合医療センター 総合診療科)

CP8-1 Team Medicine and Career development; From perspectives hospital specializing in oncology

Ayumi Saito (Department of Medical Oncology, National Cancer Center Hospital)

チーム医療とキャリア形成: がん専門病院の立場から

齋藤 亜由美 (国立がん研究センター中央病院 腫瘍内科)

CP8-2 All in One Cancer Center and Multi-disciplinary conference

Masato Nakamura (Aizawa Comprehensive Cancer Center, Aizawa Hospital)

オールインワンがんセンター、多職種カンファレンスを軸としたチーム医療

中村 将人 (相澤病院 がん集学治療センター化学療法科)

CP8-3 Multidisciplinary Team and My Career

Yuki Kumihashi (Department of Pharmacy, Tokushima Red Cross Hospital)

チーム医療と私のキャリア

組橋 由記 (徳島赤十字病院)

CP8-4 Multidisciplinary care and career formation: From nurse's position

Naomi Fujikawa (Ishikawa Prefectural Central Hospital)

チーム医療とキャリア形成: 看護師の立場から

藤川 直美 (石川県立中央病院 看護部)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

CP8-5 Doctor's Work Style Reform will become a System to Support MD's Career and Skill Enhancement

Aoi Fujikawa (Health Policy Bureau, Ministry of Health, Labour and Welfare)

チーム医療とキャリア形成：医師の働き方改革が医師のキャリアとスキルアップを支える制度となるために

藤川 葵 (厚生労働省 医政局医事課 医師等医療従事者働き方改革推進室)

15:40-16:30 Mini Oral Session 64

**MO64 Palliative Care/Symptom Management 3
緩和ケア・支持療法 3**

Chairs : Toru Okuyama (Department of Psychiatry / Palliative Care Center, Nagoya City University West Medical Center)

Satofumi Shimoyama (Aichi Cancer Center Department of Palliative Care)

司会 : 奥山 徹 (名古屋市立大学医学部附属西部医療センター 精神科・緩和ケアセンター)

下山 理史 (愛知県がんセンター 緩和ケア部)

MO64-1 Changes of anxiety and the mental condition during cancer chemotherapy

Kensuke Kamimura (Department of Pharmacy, Saiseikai Niigata Hospital / Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences)

がん薬物療法における不安や精神状態の経時的変化について

上村 賢介 (済生会新潟病院 薬剤部 / 新潟大学大学院医歯学総合研究科 腫瘍内科学分野)

MO64-2 Impact of olanzapine for chemotherapy-induced nausea and vomiting on body weight change in patients with lung cancer

Hiroe Suzuki (Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo)

肺癌患者における化学療法誘発性の悪心・嘔吐に対してオランザピンが体重に及ぼす影響

鈴木 宏依 (東京大学大学院医学系研究科 公共健康医学専攻臨床疫学・経済学)

MO64-3 The research of adverse events caused by prophylactic medication of SMX/TMP to patients with irAEs

Takayuki Shinohara (Department of Medical Training Center, Fukuchiyama City Hospital / Department of Medical Oncology, Fukuchiyama City Hospital)

irAE発症患者におけるステロイド投与下のST合剤の有害事象における検討

篠原 鷹之 (市立福知山市民病院 臨床研修センター / 市立福知山市民病院 腫瘍内科)

MO64-4 NK₁ 受容体拮抗薬ホスネツピタントのホスアプレピタント及びアプレピタントに対する有効性・安全性に関する比較検討

Hiroshi Inano (Department of Pharmacy, Kitasato University Hospital)

稲野 寛 (北里大学病院 薬剤部)

MO64-5 Survey of diabetes management in cancer patients in an oncology diabetes outpatient clinic

Haruka Kono (Department of Medical Oncology Toranomon Hospital)

当院腫瘍糖尿病外来におけるがん患者の糖尿病管理の実態調査

河野 遼 (虎の門病院 臨床腫瘍科)

Meet the Experts ① (4号館 3F 会議室 436)

8:40-9:40 Meet the Experts 14

ME14 Immunotherapy for gastroesophageal cancer: A 2024 update

E

Chairs : Keitaro Shimozaki (Kawasaki Municipal Hospital)
Kota Ouchi (Department of Medical Oncology, Tohoku University Hospital, Miyagi, Japan)
司会 : 下嵯 啓太郎 (川崎市立川崎病院)
大内 康太 (東北大学病院 腫瘍内科)

ME14 Immunotherapy for gastroesophageal cancer: A 2024 update

Sylvie Lorenzen (Klinikum rechts der Isar, University Munich, Germany)

10:20-11:20 Meet the Experts 15

ME15 Antibody-drug conjugate and Novel therapy in Lung Cancer

E

Chairs : Go Makimoto (Okayama University Hospital Department of Allergy and Respiratory Medicine)
Nobuaki Mamesaya (Division of Thoracic Oncology, Shizuoka Cancer Center)
司会 : 榎本 剛 (岡山大学病院 呼吸器・アレルギー内科)
豆鞘 伸昭 (静岡がんセンター 呼吸器内科)

ME15 Antibody-drug conjugate and Novel therapy in Lung Cancer

Byoung Chul Cho (Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Meet the Experts ② (4号館 3F 会議室 437)

8:40-9:40 Meet the Experts 16

ME16 Tumor agnostic HER2-targeted drug development

Chair : Maki Tanioka (Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)
司会 : 谷岡 真樹 (岡山大学医歯薬学域・AI人材養成産学協働プロジェクト)

ME16 Tumor agnostic HER2-targeted drug development

Kenji Tamura (Department of Medical Oncology, Shimane University Hospital)

HER2を標的とする臓器横断的な抗悪性腫瘍薬開発

田村 研治 (鳥根大学医学部附属病院 先端がん治療センター / 腫瘍内科)

10:20-11:20 Meet the Experts 17

ME17 Systemic therapy for Biliary tract cancer E

Chair : Chigusa Morizane (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)
司会 : 森實 千種 (国立がん研究センター中央病院 肝胆膵内科)

ME17 Systemic therapy for Biliary tract cancer

Do-Youn Oh (Medical Oncology, Seoul National University Hospital)

ポスター① (3号館 B1F カスケード)

13:00-13:45 Poster Session 96

- P96** Rare Cancer 1 (Central Nervous System Tumors)
希少がん 1 (脳神経)
- P96-1** **Neurocognitive state and quality of life of Moroccan patients with glioblastoma**
Mohamed Amine Baba (Faculty of medicine and pharmacy of Agadir)
- P96-2** **Utility of Lactate Dehydrogenase to Predict Prognosis in Glioma and Glioblastoma: A Systematic Review and Meta-Analysis**
Amos I. Chandra (Faculty of Medicine, Pelita Harapan University)
- P96-3** **Repurposing a world-approved drug to target Sp1 is a promising new approach to treating glioblastoma**
Wen-Bin Yang (Neuroscience Research Center, Taipei Medical University / College of Medical Science and Technology, Taipei Medical University)
- P96-4** 演題取下
- P96-5** **Role of dysregulated arachidonate metabolism in neuron-promoted glioblastoma recurrence**
Hong-Yi Lin (College of Medicine, Taipei Medical University, Taipei, Taiwan / Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan)
- P96-6** **Dendritic Cell Vaccine on Increasing Survival in Patients With Glioblastoma: A Systematic Review**
Daniel Nabasa Simanungkalit (Faculty of Medicine, Pelita Harapan University)
- P96-7** **Reprogramming of fatty acid metabolism confers to temozolomide resistance in glioblastoma**
Encore
Tsung-I Hsu (College of Medical Science and Technology, Taipei Medical University)
- P96-8** **C-Reactive Protein as Prognostic Factor in Glioma: A Systematic Review and Meta-Analysis**
Yewan Lim (Faculty of Medicine, Pelita Harapan University)
- P96-9** **Biopsy for brainstem tumors**
Yotaro Kitano (Department of Neurosurgery, Mie university)
北野 詳太郎 (三重大学 脳神経外科)

13:00-13:45 Poster Session 97

- P97** Rare Cancer 2 (Endocrine Cancer, Thyroid Cancer, Neuroendocrine Tumor)
希少がん 2 (内分泌・甲状腺 (NET/NEC 含む))
- P97-1** **The Protective Quality of Carbon Nanoparticle for Parathyroid Gland in Thyroid Cancer Surgery: A Systematic Review**
Radzikra A. Gustam (Faculty of Medicine, Pelita Harapan University)
- P97-2** **Is it lung or mediastinal? A rare case of a TTF1 positive neuroendocrine tumor presenting as superior vena cava syndrome**
Faith Abigail Kho Co (Department of Internal Medicine, St. Luke's Medical Center - Global City)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Poster Experts

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

P97-3	Treatment of pancreatic and gastrointestinal neuroendocrine neoplasms, experience in our hospital Satoru Takeji (Department of Medical Oncology, Hikone Municipal Hospital / Department of Gastroenterology, Hikone Municipal Hospital) 竹治 智 (彦根市立病院 腫瘍内科 / 彦根市立病院 消化器内科)
P97-4	A case of gastrinoma with suspected complications of carcinoid syndrome and VIPoma Okuto Koguchi (Department of Medical Oncology, Kameda Medical Center) 小口 億人 (亀田総合病院 腫瘍内科)
P97-5	A case of advanced leiomyosarcoma of bone with long disease control with multiple systemic chemotherapies Takafumi Kitazono (Department of Hematology, Oncology and Cardiovascular medicine, Kyushu University Hospital) 全身化学療法により長期病勢制御ができていた骨原発平滑筋肉腫の1例 北園 貴史 (九州大学病院 血液・腫瘍・心血管内科)
13:00-13:45 Poster Session 98	
P98	Rare Cancer 3 (Skin Cancer) 希少がん 3 (皮膚)
P98-1	Efficacy of Vemurafenib in Patients with Melanoma : A Systematic Review Ryan Christopher Harliman (Faculty of Medicine, Pelita Harapan University)
P98-2	Skin Limited Adult Langerhans Cell Histiocytosis A Rare Case : A Case Report Ni Putu Merlynda Pusvita Dewi (Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine, University of Indonesia, Jakarta)
P98-3	Effectiveness of Pembrolizumab Adjuvant Compared to Placebo in Stage 3 Melanoma: A Systematic Review Jasmine A. K Subrata (Pelita Harapan University)
P98-4	Pembrolizumab as Single Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma : A Meta Analysis Gracia S Suwongto (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)
P98-5	Effects of Antihypertensive Medication Usage Towards the Development of Non-melanoma Skin Cancers: A Systematic Review Vivian A. Chia (Pelita Harapan University)
P98-6	Efficacy Nivolumab plus Ipilimumab versus Ipilimumab alone in Patients with Advanced Melanoma: A Systematic Review Alfred Zebua (Faculty of Medicine, Pelita Harapan University / Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University)
P98-7	Efficacy of Nivolumab plus Ipilimumab versus Monotherapy against Advanced Melanoma: A Systematic Review Cynthia Marcelly Gunawan (Faculty of Medicine, Pelita Harapan University)
P98-8	Efficacy of Nivolumab Therapy for Patients with Melanoma Cancer: A Systematic Review Revany Azryna Ghoziani Heru (Faculty of Medicine, Pelita Harapan University)

13:00-13:45 Poster Session 99

- p99** Rare Cancer 4 (Sarcoma)
希少がん 4 (骨軟部)
- P99-1** **Incidence and mortality rate soft tissue sarcoma in Mongolia**
Lkhagvaochir Tovuu (Department of Oncology, Second State Central Hospital of Mongolia)
- P99-2** **Clinical Characteristics of Osteosarcoma in Tertiary Referral Cancer Center Hospital in Jakarta, Indonesia**
Chandra Sari (Division of Hematology and Oncology Medic, Internal Medicine Department, Faculty of Medicine University of Indonesia)
- P99-3** **The case report of NUT carcinoma administrated VDC-IE therapy**
Yuichiro Inagaki (Department of Oncology, Anjo Kosei Hospital / Department of Hematology, Anjo Kosei Hospital)
稲垣 裕一郎 (安城更生病院 腫瘍内科 / 安城更生病院 血液内科)
- P99-4** **A case of primary gastric leiomyosarcoma with disease control for one year with gemcitabine plus docetaxel**
Ryosuke Taguchi (Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital)
5次治療としてのゲムシタピン+ドセタキセル療法で約1年間病勢制御し得た胃原発平滑筋肉腫の1例
田口 綾祐 (九州大学病院 血液・腫瘍・心血管内科)

13:00-13:45 Poster Session 100

- P100** Rare Cancer 5 (Cancer of Unknown Primary)
希少がん 5 (原発不明がん)
- P100-1** **Clinicopathological and molecular analysis of cancer of unknown primary with chromatin remodeling gene alterations**
Yasutaka Tono (Department of Medical Oncology, Mie University Hospital)
戸野 泰孝 (三重大学医学部附属病院 血液・腫瘍内科)
- P100-2** **Clinical outcome of patients with cancer of primary unknown in the era of genomics and immune therapy**
Hiroyuki Takahashi (Department of Hematology and Medical Oncology, Kanagawa Cancer Center)
高橋 寛行 (神奈川県立がんセンター 血液・腫瘍内科)
- P100-3** **Six-year experience of patients with cancer of unknown primary: favorable group in unfavorable subsets**
Misato Ogata (Department of Medical Oncology, Hyogo Cancer Center)
緒方 美里 (兵庫県立がんセンター)

13:00-13:45 Poster Session 101

- P101** Rare Cancer 6 (Other)
希少がん 6 (その他)
- P101-1** **Role of Pembrolizumab in the Management of Microsatellite Instability-High (MSI-H) Tumors: A Systematic Review**
Mattheo MA Sumampow (Universitas Pelita Harapan)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

P101-2	NUT Carcinoma of the Lung: A Case of Immune Checkpoint Inhibitor Combination Therapy Kanako Shinada (Department of Thoracic Oncology, Kanagawa Cancer Center) 品田 佳那子 (神奈川県立がんセンター 呼吸器内科)
P101-3	Angiosarcoma of the abdominal aorta after Endovascular Aneurysm Repair. A case report Taisuke Hosokai (Department of Medical Oncology, Kyoto Katsura Hospital) 細貝 太亮 (京都桂病院 腫瘍内科)
13:00-13:45 Poster Session 102	
P102	Medical Case Report 13 (Rare Cancer 1) ケースレポート 13 (希少がん 1)
P102-1	Primary Gastric classical Hodgkins Lymphoma mimicking Gastric Cancer - A diagnostic challenge Santhosh Meedimale (Department of Medical Oncology, IMS , SUM Hospital)
P102-2	演題取下
P102-3	演題取下
P102-4	演題取下
P102-5	A Rare Case of c-KIT Mutant Metastatic Anorectal Mucosal Melanoma with Dramatic Response to Imatinib Jitnarong Karnmanee (Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital)
P102-6	Poorly differentiated carcinoma in a malignant struma ovarii successfully treated with radioactive iodine therapy Momoko Honda (Department of Medical Oncology and Hematology, Kobe University Hospital) 放射性ヨウ素内用療法が著効した悪性卵巣甲状腺腫の一例 本田 桃子 (神戸大学医学部附属病院 腫瘍・血液内科)
P102-7	A successful case of chemotherapy for primary cardiac sarcoma complicated with disseminated intravascular coagulation Jumpei Yoshida (National Hospital Organization Nagoya Medical Center, Department of Medical Oncology / Fujita Health University Hospital, Department of Medical Oncology) 吉田 淳平 (名古屋医療センター 腫瘍内科 / 藤田医科大学 臨床腫瘍科)
P102-8	トラベクテジンによる化学療法が効果であった FUS/CHOP 融合遺伝子陽性粘液型脂肪肉腫患者 4 症例 Hirohito Kirishi (Division of General Internal Medicine 4, Kawasaki Medical School) 切土 博仁 (川崎医科大学総合医療センター)
P102-9	A case of esophageal spindle cell carcinoma successfully treated with chemotherapy plus immune checkpoint inhibitor Masahiro Yaguchi (Department of Medical Oncology, National Hospital Organization Nagoya Medical Center) 免疫チェックポイント阻害薬併用化学療法が著効した切除不能食道 Spindle Cell Carcinoma の 1 例 矢口 正宏 (国立病院機構 名古屋医療センター 腫瘍内科)

- P102-10** **A case of intestinal mesenteric leiomyosarcoma with long disease control by gemcitabine + docetaxel combination therapy**
 Wakana Chikaishi (Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Hospital)
ゲムシタビン+ドセタキセル併用療法により長期間の病勢制御ができていた小腸間膜平滑筋肉腫の一例
 近石 和花菜 (岐阜大学医学部附属病院 消化器外科・小児外科)

13:00-13:45 Poster Session 103

- P103** **Medical Case Report 14 (Rare Cancer 2)**
 ケースレポート 14 (希少がん 2)
- P103-1** **Triple Threat: Thyroid Cancer, Lymphoma and Transforming Breast Cancer**
 John Kelvin M. Lalusis (St. Luke's Medical Center)
- P103-2** **Extragenital germ cell tumour of oesophagus in a young female patient**
 Warunporn Siriboonpipattana (Department of Medical Oncology, Khon Kaen University)
- P103-3** **演題取下**
- P103-4** **The low apparent diffusion coefficient in an extracranial brain tumor: a case report**
Encore Duy Quang Ngo (Department of Radiology, VietDuc General Hospital)
- P103-5** **Malignant Peritoneal Mesothelioma Treated with Pembrolizumab & Lenvatinib, Cytoreductive Surgery & HIPEC: A Case Report**
 Noelle Karla Maniya P. Japzon (Section of Medical Oncology, Southern Philippines Medical Center)
- P103-6** **Solitary Extramedullary Plasmacytoma of The Cervix: A Case Report**
 Beta A Wisman (Division of Hematology-Medical Oncology, Department of Internal Medicine, Medical Faculty University of Indonesia-Cipto Mangunkusumo General Hospital)
- P103-7** **Primary intraventricular gliosarcoma on MRI: A challenging diagnosis**
Encore Vi Ha Nguyen (Department of Radiology, Hanoi Medical University)
- P103-8** **Magnetic resonance imaging characteristics of glioblastoma of the optic pathway during adulthood**
Encore Duy Quang Ngo (Department of Radiology, VietDuc General Hospital)
- P103-9** **Partial response to docetaxel and gemcitabine chemotherapy in a patient with HG-ESS stage IV : A case report**
 Fujio Yamamoto (Yamato Municipal Hospital)
高異型度子宮内膜間質肉腫IVB期の患者に対し、DG療法により部分奏功を得られた一例
 山本 藤尾 (大和市立病院)

13:00-13:45 Poster Session 104

- P104** **Medical Case Report 15 (Rare Cancer 3)**
 ケースレポート 15 (希少がん 3)
- P104-1** **演題取下**
- P104-2** **EMBRYONAL RHABDOMYOSARCOMA OF BLADDER IN ADULT MANAGED WITH VINCRISTINE DOXORUBICIN CYCLOPHOSPHAMIDE FOLLOWED BY SURGERY**
Encore Kristine G. Tejada (National Kidney and Transplant Institute, Section of Medical Oncology)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) On-demand Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

- P104-3 Comprehensive Genomic Analysis of Advanced Melanoma with Low to No UV Radiation Exposure in Asian Patients**
Yu-Ting Lin (Department of Surgery, Taichung Veterans General Hospital, Taiwan)
-
- P104-4 Efficacy of pazopanib for recurrent meningeal hemangiopericytoma: a report of three cases at our hospital**
Shinya Tokunaga (Department of Medical Oncology, Osaka City General Hospital)
再発髄膜血管外皮腫に対するPazopanibの効果：当院における3例の報告
徳永 伸也 (大阪市立総合医療センター 腫瘍内科)
-
- P104-5 A case of pleomorphic rhabdomyosarcoma of primary rectus abdominis muscle with MSH2 pathogenic variant**
Akinori Sugaya (Department of Medical Oncology, Ibaraki Prefectural Central Hospital)
MSH2病的バリエントを認めた腹直筋原発の多形型横紋筋肉腫の一例
菅谷 明徳 (茨城県立中央病院・茨城県地域がんセンター 医療局 腫瘍内科)
-
- P104-6 An ACTH-Producing Primary Hepatic Neuroendocrine Tumor; Clinical Course of Multidisciplinary Therapy Including PRRT**
Tomonobu Koizumi (Department of Internal Medicine, Nagano Prefectural Kiso Hospital)
小泉 知展 (長野県立木曽病院 内科)
-
- P104-7 Sarcomatoid carcinoma of unknown primary successfully managed by pembrolizumab**
Yasutsuna Sasaki (Department of Medical Oncology, Rakuwakai-Otowa Hospital)
ペンプロリズマブが奏効した原発不明肉腫様がん
佐々木 康綱 (洛和会音羽病院 腫瘍内科)
-
- P104-8 A case of malignant melanoma arising ovarian teratoma**
Kaho Shimizu (Department of Medical Oncology, Kameda Medical Center)
卵巣奇形腫から発生した悪性黒色腫の1例
清水 花穂 (亀田総合病院 腫瘍内科)
-
- P104-9 Efficacy of trametinib in neurofibromatosis type 1 associated gastrointestinal stromal tumors: case report**
Misao Fukuda (Department of Medical Oncology, National Cancer Center Hospital East)
神経線維腫症1型に併存した多発性小腸GISTに対してMEK阻害薬が奏効した一例
福田 美佐緒 (国立がん研究センター東病院 腫瘍内科)
-
- P104-10 A Case of Cardiac Intimal Sarcoma with Amplifications of MDM2 and PDGFR**
Takumi Sano (Postgraduate Medical Education Center, Kameda Medical Center)
MDM2およびPDGFR増幅を伴った心臓内膜肉腫の一例
佐野 匠 (亀田総合病院 卒後研修センター)

ポスター② (4号館 1F 白鳥ホール (展示内))

13:00-13:45 Poster Session 105

P105 Genitourinary Cancer 1
泌尿器 1

- P105-1 Propofol-Based Total Intravenous Anesthesia is Beneficial in Prostate Cancer Treatment**
Szu-Yuan Wu (Asia University, Taiwan / Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan)
- P105-2 Safety and Efficacy of Olaparib in Metastatic Castration-Resistant Prostate Cancer with DNA Damage Repair Aberrations**
Raenen Liauw (Pelita Harapan University)
- P105-3 Assessing the Efficacy of Ipilimumab as Prostate Cancer Treatment: A Systematic Review**
Timothy Victoryno (Faculty of Medicine, Pelita Harapan University, Indonesia)
- P105-4 Combination of CAPE with ENZ or AA suppresses drug-resistant PCa via degradation of AR-V7 and interference of metabolism**
Ying-Yu Kuo (Institutes of Cellular and System Medicines, National Health and Research Institute, Taiwan)
- P105-5 Efficacy of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma: A Systematic Review**
Claresta J. Budianto (Faculty of Medicine, Pelita Harapan University)
- P105-6 Comparative Effectiveness of Nivolumab versus Sunitinib in Patients with RCC: a Systematic review and Meta-analysis**
William Surya Atmaja (Faculty of Medicine, Pelita Harapan University)
- P105-7 演題取下**
- P105-8 Validation study of PLaCT classification for malignant ureteral obstruction in patients treated with metallic stents**
Taiki Kamijima (Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science)
腫瘍性尿管狭窄患者における金属ステントを用いた予後予測分類 (PLaCT分類) の妥当性の検証
神島 泰樹 (金沢大学医薬保健学総合研究科 泌尿器集学的治療学)
- P105-9 Safety of dose-dense MVAC with pegfilgrastim in patients with urothelial carcinoma**
Takahiro Harano (Department of Urology, Kitasato University School of Medicine)
原野 貴弘 (北里大学医学部 泌尿器科学)
- P105-10 Efficacy and Safety of TKI following IO combination therapy in elderly patients with metastatic renal cell carcinoma**
Tetsuaki Hayashi (Department of Urology, Faculty of Medicine, University of Toyama)
高齢転移性腎細胞癌患者におけるIO併用療法後のTKIの有効性と安全性
林 哲章 (富山大学学術研究部医学系 腎泌尿器科学講座)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Poster Experts

13:00-13:45 Poster Session 106

- P106** Genitourinary Cancer 2
泌尿器 2
- P106-1** **Efficacy of Olaparib in Patients with Metastatic Castration-Resistant Prostate Carcinoma: Meta-analysis**
Nyoman B. S. A. Purushotama (Faculty of Medicine, Pelita Harapan University)
- P106-2** **Efficacy and Safety of Apalutamide for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review**
Jason P Tejayadi (Faculty of Medicine, Pelita Harapan University)
- P106-3** **APPLICATION OF CERROBEND TESTICULAR SHIELD BY 3D PRINTING AND METAL CUTTING IN RADIOTHERAPY PATIENTS: A PILOT STUDY**
Muhammad Iqbal Maulana (Department of Radiation Oncology, Hospital Indonesia)
- P106-4** **Combination Cabozantinib with Nivolumab as Initial Treatment in Patients with Renal-Cell Carcinoma: A Systematic Review**
Sherina Kosayuz (Department of Medicine, Pelita Harapan University)
- P106-5** **Efficacy and Safety of Rucaparib as Potential Treatment for Metastatic Prostate Cancer Patients: A Systematic Review**
Ayu I.U. Amalia (Faculty of Medicine, Pelita Harapan University)
- P106-6** **Risk factors for recurrence after curative nephrectomy in non-metastatic Renal Cell CA: a retrospective cohort study**
Kristine G. Tejada (National Kidney and Transplant Institute, Section of Medical Oncology)
- P106-7** 演題取下
- P106-8** **Safety and Efficacy of Enfortumab vedotin administered biweekly for Urothelial Carcinoma**
Ryunosuke Nakagawa (Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science)
尿路上皮がんに対する Enfortumab vedotin の biweekly 投与における安全性と有効性についての検討
中川 竜之介 (金沢大学大学院医学系研究科 集学的治療分野)
- P106-9** **Bone modifying agents prevent urothelial cancer patients with bone metastasis from experiencing skeletal related events**
Shuhei Aoyama (Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science)
青山 周平 (金沢大学医薬保健学総合研究科 泌尿器集学的治療学)
- P106-10** **Initial clinical experience of dd-MVAC as neoadjuvant chemotherapy for patients with locally advanced bladder cancer**
Yutaka Okumura (University of Occupational and Environmental Health Urology)
局所浸潤性膀胱癌に対し術前化学療法での dd-MVAC 療法の初期経験
奥村 豊 (産業医科大学 泌尿器科)
- P106-11** **Enhanced Efficacy of ICIs with RT in RCC: A Statistical Analysis of 37 Cases from the DARC-MICAN Study**
Shunsuke Haga (Department of Urology, Ehime University of Medicine)
芳賀 俊介 (愛媛大学医学部附属病院 泌尿器科)

P107	Genitourinary Cancer 3 泌尿器 3
P107-1	演題取下
P107-2	Efficacy and Safety of Apalutamide in Patients with Prostatic Neoplasm: A Systematic Review Verlin A. Laiman (Faculty of Medicine, Pelita Harapan University)
P107-3	SBRT and IMRT in Localized Prostate Cancer: Genitourinary Toxicity Comparison Angelina Wandana (Faculty of Medicine, Pelita Harapan University, Indonesia)
P107-4	OCCULT METASTATIC PROSTATE ADENOCARCINOMA PRESENTING WITH GENERALIZED LYMPHADENOPATHY IN AN ELDERLY MAN: A CASE REPORT Gale Rizzae M. Alcala (Section of Medical Oncology, St. Luke's Medical Center, Philippines)
P107-5	De Novo Adenosquamous Carcinoma of the Prostate: A Case Report Cristina G Domingo (Cancer Institute St Lukes Medical Center Quezon City)
P107-6	演題取下
P107-7	Early experience of the genomic profiling test for castration-resistant prostate cancer performed in our hospital Fumihiro Ito (Gifu Prefectural Tajimi Hospital) 当院で施行された去勢抵抗性前立腺癌患者に対する遺伝子パネル検査とオラパリブ投与症例の検討 伊藤 史裕 (岐阜県立多治見病院)
P107-8	Risk factors for recurrence in pathologically advanced renal cancer after nephrectomy Ren Toriumi (Integrative Cancer Therapy and Urology, Division of Cancer Medicine, Graduate School of Medical Science, Kanazawa University) 外科的治療後の病理学的進行腎癌における再発予測因子の検討 鳥海 蓮 (金沢大学大学院医学系研究科 泌尿器集学的治療学)
P107-9	Report of 5 cases treated with pembrolizumab and lenvatinib combination therapy for renal cell carcinoma Akiyuki Yamamoto (Department of Urology Toyohashi Municipal Hospital) 腎癌に対するペムブロリズマブ、レンバチニブ併用療法を施行した5例の報告 山本 晃之 (豊橋市民病院 泌尿器科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
On-demand
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

ポスター③ (4号館 3F 438)

13:00-13:45 Poster Session 108

P108 Artificial Intelligence (AI)
人工知能 (AI)

P108-1 演題取下

P108-2 **Machine learning application in colorectal cancer screening from histopathology whole slide images**

Ellie S.M. Chu (School of Medical and Health Sciences, Tung Wah College, Hong Kong SAR)

P108-3 **Oncology Drug Regimen Prediction using Machine Learning for Knowledge Graph**

Mariko Nio (Chugai Pharmaceutical Co., Ltd.)

ナレッジグラフにおける機械学習によるがん治療薬レジメン予測

丹尾 真理子 (中外製薬株式会社)

P108-4 **Advancing Skin Cancer Detection: Real-Time Deep Learning with Dermoscopy Images for Improved Patient Outcomes**

Rifaldy Fajar (Department of Mathematics and Computer Science, Karlstad University)

P108-5 **AI-Driven Drug Discovery for BRAF-Mutated Melanoma: Accurate Prediction of Drug Response Rates and Molecular Insights**

Rifaldy Fajar (Department of Mathematics and Computer Science, Karlstad University)

P108-6 **The Role of Artificial Intelligence in Non-small cell Lung Cancer Diagnosis : A systematic Review**

Cherinna K. Prayadi (Faculty of Medicine, Pelita Harapan University)

P108-7 **Advancements in Artificial Intelligence for Early Cancer Detection in Oncology: A Systematic Review**

Volney B. Lambert (Faculty of Medicine, Pelita Harapan University)

P108-8 **Using machine learning to select effective local treatment groups for solid tumors with distant metastases**

Yuichi Sakamoto (Division of Translational Informatics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Japan / Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo)

機械学習を用いた遠隔転移を有する固形癌に対する局所治療有効群の選別

坂本 優一 (国立がん研究センター 先端医療開発センター トランスレーショナルインフォマティクス分野 / 東京大学大学院 新領域創成科学研究科 メディカル情報生命専攻)

P108-9 **A Systematic Review on the Radiomics Classification of Chordoma using Machine Learning**

Jeremiah H Wijaya (Department of Neurosurgery, Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Banten, Indonesia)

P108-10 **Opportunities of Artificial Intelligence in Liver Cancer Diagnosis: A Systematic Review of Randomized Controlled Trials**

Edeline Samudra (Pelita Harapan University)

ポスター④ (3号館 3F 3F 通路)

13:00-13:45 Poster Session 109

P109 Head and Neck Cancer 1
頭頸部 1

- P109-1 Acute and Late Radiation-Related Toxicities in IMPT versus IMRT for Nasopharyngeal Cancer**
Szu-Yuan Wu (Asia University, Taiwan / Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan / Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan)
- P109-2 The clinical impact of TP53 mutations in head and neck cancer patients treated with targeted therapies or immunotherapy**
Eun Joo Kang (Department of Hemato-oncology, Division of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea)
- P109-3 Statin Use Reduces Radiation-Induced Stroke Risk in Advanced Nasopharyngeal Carcinoma Patients**
Szu-Yuan Wu (Asia University, Taiwan / Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan / Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan)
- P109-4 Nomogram for Prognostication of Oral Squamous Cell Carcinoma Recurrence**
Akbar Shoukat (Department of Medicine, Aga Khan University)
- P109-5 An audit of multimodality cancer-directed therapy in margin positive & extra nodal extension for oral cavity carcinomas**
Abhilash Dagar (Department of Radiation Oncology, NCI-AIIMS)
- P109-6 Analysis of NLRP3 Inflammasome in OSCC, Potentially Malignant Oral Disorders (PMODs) and its Correlation with Serum IL- β 1**
Trupti Jain (Faculty of Dental Sciences, Institute of Medical Sciences, BHU)
- P109-7 Defining a group of oligometastatic nasopharyngeal carcinoma patients with improved survival outcomes**
Wanyi Kee (National Cancer Centre Singapore)
- P109-8 Associations Between High-risk Sexual Behaviors, HPV, and Head & Neck Cancer: Meta-analytic Structural Equation Modeling**
Peesit Leelasawatsuk (Faculty of Medicine, Prince of Songkla University)
- P109-9 Efficacy of Pembrolizumab-Chemotherapy vs. Cetuximab-Chemotherapy in Head and Neck Squamous Cell Carcinoma**
Teresa Jeanice (Faculty of Medicine, Pelita Harapan University)

13:00-13:45 Poster Session 110

P110 Head and Neck Cancer 2
頭頸部 2

- P110-1 Treatment outcomes of stage IV B (N3) head & neck cancer treated with Concurrent chemoradiotherapy**
Aman Sharma (Department of Radiation Oncology, National Cancer Institute,)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

On-demand

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Poster Experts

Poster

Day 1 (Thu)	P110-2	HPV ASSOCIATED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA IN TANZANIA Godwin Abdiel Nnko (Department of Clinical Oncology , Muhimbili University of Health and Allied Sciences)
Day 2 (Fri)	P110-3	演題取下
Day 3 (Sat)	P110-4	Low compared to High Dose Regimen of Induction chemotherapy in Nasopharyngeal Cancer: A Systematic Review Meta-Analysis Andree Kurniawan (Faculty of Medicine, Pelita Harapan University / Trainee, hematology and medical oncology, Internal Medicine, Faculty of Medicine, Universitas Indonesia)
On-demand Room 1	P110-5	Efficacy and Safety Comparison of Radiotherapy alone with or without Chemotherapy in Nasopharyngeal Carcinoma Ega Budiarti (Faculty of Medicine, Pelita Harapan University)
Room 2	P110-6	Three-Dimensional (3-D) Endoscopy in Neurosurgery: Preliminary Experience Dattaraj P Sawarkar (Department of Neurosurgery, CNC, AIIMS, Ansari Nagar)
Room 3	P110-7	Efficacy and Safety of Pembrolizumab in Recurrent or Metastatic Head and Neck Carcinoma as first line therapy Kazue Ito (Miyagi Cancer Center Head and Neck Oncology)
Room 4		再発転移頭頸部がんに対する一次治療としてのペムブロリズマブ療法の治療成績と安全性 伊東 和恵 (宮城県立がんセンター 頭頸部内科)
Room 5	13:00-13:45 Poster Session 111	
Room 6	P111	Head and Neck Cancer 3 頭頸部 3
Room 7	P111-1 Encore	Patient experience using Tumor Treating Fields (TTFields) therapy for glioblastoma Kentaro Enjo (Novocure Ltd)
Room 8	P111-2	Hippocampal Sparing during Whole Brain Radiotherapy and Preservation of Neurocognitive Function for Brain Metastasis Alexa O Tan (Department of Medicine, Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Banten, Indonesia)
Room 9	P111-3	Preoperative Prognostic Nutritional Index for Patients with Glioblastoma: A Systematic Review and Meta-Analysis Aurelia MC Agus (Department of Medicine, Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Banten, Indonesia)
Room 10	P111-4	Differentiation of glioblastoma and primary central nervous system lymphoma using diffusion and perfusion MRI Ngoc Anh Nguyen (Hanoi Medical University)
Room 11	P111-5 Encore	Discriminating glioblastoma from solitary brain metastases: the roles of fractional anisotropy and mean diffusivity Vi Ha Nguyen (Department of Radiology, Hanoi Medical University)
Room 12	P111-6 Encore	Diagnostic performance of diffusion tensor imaging for preoperative glioma grading Hung Duy Nguyen (Department of Radiology, Hanoi Medical University)
Room 13	P111-7	演題取下
Meet the Experts Poster		

P112	Head and Neck Cancer 4 頭頸部 4
P112-1	演題取下
P112-2	Discrimination between glioblastoma and solitary brain metastasis: a quantitative study based on FLAIR signal intensity Nguyen Thi Hai Anh (Department of Radiology, Hanoi Medical University)
P112-3 Encore	The role of magnetic resonance perfusion and spectroscopy in distinguishing glioblastoma from solitary brain metastasis Vi Ha Nguyen (Department of Radiology, Hanoi Medical University)
P112-4	Extraventricular neurocytoma: A neuronal tumor with a mysterious prognosis Niveditha Manjunath (Department of Neurosurgery, Fortis Memorial Research Institute)
P112-5	演題取下
P112-6	Efficacy and Safety of Dabrafenib as a Potential Treatment for Pediatric Patients with BRAF V600-Mutant Low-Grade Glioma Michella J. Pamula (Faculty of Medicine, Pelita Harapan University, / Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University)
P112-7	Brentuximab Vedotin in Combination with AVD versus ABVD for Hodgkin Lymphoma: A Systematic Review and Meta-Analysis Cecilia E.O.L. Hutauruk (Faculty Of Medicine, Pelita Harapan University)

ポスター⑤ (2号館 3F 3F ホワイエ)

13:00-13:45 Poster Session 113

P113 Gynecologic Cancer 1
婦人科 1

- P113-1** **Impact of General Anesthesia versus Regional Anesthesia on Oncologic Outcomes in Early Stage Cervical Cancer**
Szu-Yuan Wu (Asia University, Taiwan / Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan)
- P113-2** **Clinical Characteristics and Treatment Outcomes of Metastatic Ovarian Cancer in Bangladesh: A Retrospective Study**
Mst. Fatema Akter (Biochemistry and molecular biology Department, Gono Bishwabidyalay)
- P113-3** **Comparison Between HPV Test and Liquidbased Cytology for Cervical Cancer Detection:A Systematic Review and MetaAnalysis**
Cecilia A Sutedja (Faculty of Medicine, Pelita Harapan University)
- P113-4** **Progression Free Survival of Niraparib in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: Meta-Analysis**
Nyoman B. S. A. Purushotama (Faculty of Medicine, Pelita Harapan University)
- P113-5** **Efficacy and Safety of Niraparib in Patients with Recurrent Ovarian Cancer: Systematic Review**
Anissa D. Fadhila (Faculty of Medicine, Pelita Harapan University)
- P113-6** **The Efficacy of Olaparib in BRCA Mutated Ovarian Cancer : A Systematic Review**
Maria Georgina Wibisono (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)
- P113-7** **Serum STN in patients with endometrial cancer**
Yasunori Hashiguchi (Department of Gynecology, Ishikiriseiki Hospital)
橋口 裕紀 (石切生喜病院 婦人科)
- P113-8** **Outcomes of Early-Phase Clinical Trials in Gynecological Cancer: A Single-Center, Retrospective Study**
Misao Fukuda (Department of Medical Oncology, National Cancer Center Hospital East)
福田 美佐緒 (国立がん研究センター東病院 腫瘍内科)

13:00-13:45 Poster Session 114

P114 Gynecologic Cancer 2
婦人科 2

- P114-1** **Safety and Efficacy Rucaparib in ovarian cancer: A Systematic Review**
Paulina Bellen (Faculty of Medicine, Pelita Harapan University)
- P114-2** **Abnormalities plasma Lipid Profile in Gynecologic Cancers: A Systematic Review and Meta-Analysis**
Salsabila Nabilah Rifdah (Airlangga University)
- P114-3** **Combination of LEN with PEMBRO Used as a Drug Therapy for Advanced Endometrial Cancer Patients: A Systematic Review**
Valentine W. M. Kayame (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)
- P114-4** 演題取下

- P114-5 Gemcitabine Combination vs Gemcitabine Alone in Platinum-Resistant/Refractory Ovarian Cancer: A Systematic Review**
Michael Gerald Lokanata (Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia)
- P114-6 Efficacy and Safety of Pembrolizumab in Patients with Uterine Neoplasms: A Systematic Review**
Sinta A. Nariswari (Faculty of Medicine, Pelita Harapan University)
- P114-7 Treatment strategies after comprehensive genomic profiling tests for advanced cervical cancer patients**
Xiaofei Wang (Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research)
王 晓斐 (がん研究会 有明病院 総合腫瘍内科)
- P114-8 Monitoring of CA125 levels during initial treatment for ovarian cancer may be an alternative to RECIST**
Kento Kato (Department of Clinical Oncology, National Defense Medical College Hospital / Department of Obstetrics and Gynecology, National Defense Medical College Hospital)
加藤 顕人 (防衛医科大学校病院 腫瘍化学療法部 / 防衛医科大学校病院 産婦人科)